denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Waack, K.
Waage, A.
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
Waanders, E.
Waddicor, P.
Wadelin, F.
Wader, K. F.
235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
Wadham, C.
991 - Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
Wadhwa, A.
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report
3721 - Household Poverty and Risk of Obesity during Maintenance Therapy for Childhood Acute Lymphoblastic Leukemia (ALL): Children’s Oncology Group (COG) Study AALL03N1 Report
3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report
3721 - Household Poverty and Risk of Obesity during Maintenance Therapy for Childhood Acute Lymphoblastic Leukemia (ALL): Children’s Oncology Group (COG) Study AALL03N1 Report
Wadhwa, M. P.
Wadleigh, M.
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
Wadley, L.
Wadsworth, K.
Wafi, Z.
Wafula, E. K.
Wagen, L. V.
Wagenblast, E.
Wagener-Ryczek, S.
Wagner, C.
Wagner, C. B.
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
2382 - Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience
5026 - Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
2382 - Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience
5026 - Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement
Wagner Drouet, E.
Wagner Drouet, E. M.
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
2875 - Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
2875 - Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
Wagner, E. J.
Wagner, J. R.
Wagner, J.
Wagner, J. E.
Wagner, K.
Wagner, T. R.
Wagner, T.
55 - A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial
60 - AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
60 - AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
Wagner-Johnston, N. D.
236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
Wahab, A.
Wahby, N.
Waheed, R.
Wahida, A.
Wahlestedt, C.
Wahlin, B. E.
654 - Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study
3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
Wahlster, L.
953 - Targeted Protein Degradation Reveals a Repressive Role of Mecom at the CEBPA Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia
4039 - Transcription Factor Networks Disproportionately Enrich for Heritability of Blood Cell Phenotypes
- Elucidating the Mechanisms of Genetic Susceptibility in Childhood Acute Lymphoblastic Leukemia through the Lens of Genomics
4039 - Transcription Factor Networks Disproportionately Enrich for Heritability of Blood Cell Phenotypes
- Elucidating the Mechanisms of Genetic Susceptibility in Childhood Acute Lymphoblastic Leukemia through the Lens of Genomics
Wahlstrom, S. K.
5105 - Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets
5109 - Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
5109 - Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Wain-Hobson, S.
Wainman, B.
235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank
1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank
Waisgerber, S. M.
Wajant, H.
Wakamatsu, M.
Wake, A.
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
Wake, A.
Wakiro, I.
Wakulinska, A.
Wald, M.
Walden, J.
Waldron, C.
Waldschmidt, J.
284 - Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations
593 - Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
3267 - GPRC5D Status Impacts CD38 Expression in Multiple Myeloma
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
4639 - Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia
4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma
4714 - Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature
593 - Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
3267 - GPRC5D Status Impacts CD38 Expression in Multiple Myeloma
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
4639 - Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia
4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma
4714 - Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature
Walenciak, J.
Walewski, J.
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
Walewski, J.
237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
Walgenbach, D.
Walia, M.
476 - Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare
1721 - Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma
1721 - Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma
Walia, R.
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Waliagha, R.
Walker, A. R.
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1843 - High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3227 - Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
- Career Development and Job Searching
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1843 - High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3227 - Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
- Career Development and Job Searching
Walker, B. A.
768 - Multiomics Data Integration in the Complete Myeloma Genome Reveals Frequent Centromeric Rearrangements and Their Epigenomic Consequences
857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
1882 - Phylogenetic Analysis Reveals Distinct Evolutionary Patterns in Multiple Myeloma Patient Derived Xenografts
4644 - Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4657 - Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment
4667 - Non-Hotspot DIS3 Mutations in Multiple Myeloma Result in Loss of Function Accompanied By Transcriptional and Proteomic Dysregulation
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
1882 - Phylogenetic Analysis Reveals Distinct Evolutionary Patterns in Multiple Myeloma Patient Derived Xenografts
4644 - Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4657 - Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment
4667 - Non-Hotspot DIS3 Mutations in Multiple Myeloma Result in Loss of Function Accompanied By Transcriptional and Proteomic Dysregulation
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Walker, C.
Walker, C. J.
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
1377 - Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
1377 - Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
Walker, H. A.
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Walker, I.
Walker, I.
2764 - The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid
3519 - A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)
3519 - A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)
Walker, J. S.
Walker, M.
Walker, M. E.
Walker, M.
Walker, Q.
Walker, S.
933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
Walker, Z. J.
Walkovich, K. J.
162 - Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC)
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
3489 - Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
3489 - Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study
Wall, D.
Wall, J. S.
Wall, S. A.
685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
3446 - Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
- Adult Malignant Hematology
3446 - Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
- Adult Malignant Hematology
Wall, V.
Wallace, D. S.
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
3819 - Reverse Morning Report: A Case-Based, Fellow-Lead, Curriculum for Internal Medicine Residents Rotating on the Inpatient Malignant Hematology Service
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
3819 - Reverse Morning Report: A Case-Based, Fellow-Lead, Curriculum for Internal Medicine Residents Rotating on the Inpatient Malignant Hematology Service
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
Wallace, J.
Wallace, K.
Wallace, L.
Wallace, L. K.
638 - Dysregulation of Developmental Transcription Factors in Acute Myeloid Leukemia Predicts Poor Outcome and Impacts Adaptive Immune Pathway Genes
849 - Comprehensive Characterization of Rare Recurrent Mutations in Pediatric AML
1562 - Haplo-Insufficiency of RAS Genes Is the Determinant of Outcome in AML
2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
2925 - The AML HOX-Ome: The Landscape of Developmental Transcription Factors across Pediatric Acute Myeloid Leukemia
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
849 - Comprehensive Characterization of Rare Recurrent Mutations in Pediatric AML
1562 - Haplo-Insufficiency of RAS Genes Is the Determinant of Outcome in AML
2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
2925 - The AML HOX-Ome: The Landscape of Developmental Transcription Factors across Pediatric Acute Myeloid Leukemia
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
Walldin, G.
Waller, A.
789 - Characterization of an Oral Oncology Drug Repository Program for Hematology and Hematopoietic Cell Transplant Patients at a Comprehensive Cancer Center
1771 - Comparison of Long-Term Outcomes Among Patients with Chronic Myeloid Leukemia Who Undergo Initial Tyrosine Kinase Inhibitor Dose Reduction Versus Tyrosine Kinase Inhibitor Switch
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
5049 - Understanding Valuation of Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia Using a Novel Hypothetical Purchasing Task
1771 - Comparison of Long-Term Outcomes Among Patients with Chronic Myeloid Leukemia Who Undergo Initial Tyrosine Kinase Inhibitor Dose Reduction Versus Tyrosine Kinase Inhibitor Switch
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
5049 - Understanding Valuation of Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia Using a Novel Hypothetical Purchasing Task
Waller, A.
Waller, B.
Waller, E. K.
382 - Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
3521 - Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis
4299 - VIP Expression Drives an Immunosuppressive Tumor Microenvironment in TP53-Mutated AML
4914 - The Dominant Effect of the Gut Microbiome on GvHD in Mouse Models of Allo-BMT
4964 - Development of Humanized Antibodies Against Vasoactive Intestinal Polypeptide for Increased T Cell Anti-Leukemia Activity
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
3521 - Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis
4299 - VIP Expression Drives an Immunosuppressive Tumor Microenvironment in TP53-Mutated AML
4914 - The Dominant Effect of the Gut Microbiome on GvHD in Mouse Models of Allo-BMT
4964 - Development of Humanized Antibodies Against Vasoactive Intestinal Polypeptide for Increased T Cell Anti-Leukemia Activity
Waller, J.
1135 - Characterizing People with Sickle Cell Disease Who Share Attitudes Regarding Clinical Trial Participation: Findings from the Global LISTEN Survey
1137 - How People with Sickle Cell Disease Rate Motivators is Associated with the Likelihood of Wanting to Participate in a Clinical Trial: Findings from the Global LISTEN Survey
1137 - How People with Sickle Cell Disease Rate Motivators is Associated with the Likelihood of Wanting to Participate in a Clinical Trial: Findings from the Global LISTEN Survey
Waller, R. G.
Wallin, M.
Wallin, S.
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
Walling, J. M.
1908 - OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC
4141 - RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions
4141 - RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions
Wallis, L.
Wallis, W.
Walsh, C.
Walsh, M.
Walsh, M. P.
Walsh, T. P.
Walter, D.
Walter, H. S.
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3591 - ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies
3591 - ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies
Walter, J.
Walter, M. J.
224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
1833 - Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy
3220 - Robust Copy Number Alteration Detection (RCNA): A Novel Algorithm for Detecting Copy-Number Alterations for Targeted Gene Sequencing Experiments
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
1833 - Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy
3220 - Robust Copy Number Alteration Detection (RCNA): A Novel Algorithm for Detecting Copy-Number Alterations for Targeted Gene Sequencing Experiments
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
Walter, P. B.
Walter Petrich, A.
Walter, R. B.
265 - CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
1530 - 4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
2014 - CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model
2414 - Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024
2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
4288 - Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy
1530 - 4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
2014 - CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model
2414 - Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024
2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
4288 - Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy
Walter, T.
Walter, W.
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
2676 - Single-Cell Transcriptomics of Bone Marrow Mesenchymal Stromal Cells Identifies Altered CLCF1 Signaling in DNMT3A-Mutated Clonal Hematopoiesis
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
2676 - Single-Cell Transcriptomics of Bone Marrow Mesenchymal Stromal Cells Identifies Altered CLCF1 Signaling in DNMT3A-Mutated Clonal Hematopoiesis
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
Walters, M. C.
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
4955 - Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
4955 - Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial
Walters, S.
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
Walther, D.
Walther, T.
Waltz, G.
Walz, G.
Walz, J. S.
3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia
1504.1 - Trial in Progress: Phase I Trial Evaluating an Immunopeptidome-Defined Multi-Peptide Vaccine Against Acute Myeloid Leukemia Stem and Progenitor Cells
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
1504.1 - Trial in Progress: Phase I Trial Evaluating an Immunopeptidome-Defined Multi-Peptide Vaccine Against Acute Myeloid Leukemia Stem and Progenitor Cells
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
Walzog, B.
Wambacq, S.
Wambaka, B.
Wan, B.
Wan, C. L.
1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
Wan, F.
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
985 - Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
985 - Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
Wan, G.
Wan, X.
2138 - Effective Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease with Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (iMSC) in a Clinical Setting
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
Wan, X.
Wan, X.
Wan, X.
1896 - Proteasome Shuttle Factor and DNA Repair Protein Rad23A Is a Potential Therapeutic Target in Multiple Myeloma
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
Wan, Y.
1162 - Ras-Associated Autoimmune Lymphoproliferative Disorder: Retrospective Case Series
1322 - Distinguishing Childhood Non-Severe Aplastic Anemia from Dyskeratosis Congenita through Telomere Length Analysis
2120 - Development and Validation of a prediction model for severe PES during the treatment of unrelated UCBT in pediatric patients
2174 - Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 86 Pediatric Patients with Aplastic Anemia: A Single-Center Experience
2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study
4188 - Relapse Risk and Outcome of Discontinuing Asparaginase in Children with Acute Lymphoblastic Leukemia
1322 - Distinguishing Childhood Non-Severe Aplastic Anemia from Dyskeratosis Congenita through Telomere Length Analysis
2120 - Development and Validation of a prediction model for severe PES during the treatment of unrelated UCBT in pediatric patients
2174 - Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 86 Pediatric Patients with Aplastic Anemia: A Single-Center Experience
2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study
4188 - Relapse Risk and Outcome of Discontinuing Asparaginase in Children with Acute Lymphoblastic Leukemia
Wan, Y.
998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
3210 - Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
3210 - Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
Wan, Y. C. S.
Wan, Z.
Wanchai, V.
Wandroo, F. A.
Wang, A.
Wang, A.
Wang, A.
Wang, A. W.
1703 - Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study
2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Wang, A.
Wang, A.
1801 - Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
Wang, B.
Wang, B.
1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
Wang, B.
Wang, B.
Wang, B.
Wang, B.
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2213 - ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples
2766 - Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients
2911 - Multi-Omic Analyses of TP53-Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
3236 - Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD
4219 - Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2213 - ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples
2766 - Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients
2911 - Multi-Omic Analyses of TP53-Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
3236 - Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD
4219 - Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin
Wang, B.
Wang, B.
Wang, B.
2353 - Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
3253 - Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton’s Tyrosine Kinase Inhibitors (BTKi)
3253 - Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton’s Tyrosine Kinase Inhibitors (BTKi)
Wang, B.
Wang, C.
1413 - Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing
1675 - The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study
1675 - The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study
Wang, C.
Wang, C.
Wang, C. C.
300 - Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
1486 - Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
2041 - Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs
1486 - Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
2041 - Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs
Wang, C. K.
Wang, C.
Wang, C.
Wang, C. K.
Wang, C.
1685 - Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
2882 - High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study
3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
2882 - High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study
3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients
Wang, C.
Wang, C.
833 - ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24
956 - A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells
2779 - PRPS2 Facilitates the Tumorigenesis of Diffuse Large B-Cell Lymphoma By Promoting Fatty Acid β-Oxidation
956 - A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells
2779 - PRPS2 Facilitates the Tumorigenesis of Diffuse Large B-Cell Lymphoma By Promoting Fatty Acid β-Oxidation
Wang, D.
277 - Sex, Lies, and Iron Deficiency in 2024: Cost-Effectiveness of Screening Ferritin Thresholds for the Treatment of Iron Deficiency in Women of Reproductive Age
281 - Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
601 - Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease
281 - Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
601 - Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease
Wang, D. Y.
277 - Sex, Lies, and Iron Deficiency in 2024: Cost-Effectiveness of Screening Ferritin Thresholds for the Treatment of Iron Deficiency in Women of Reproductive Age
281 - Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
281 - Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
Wang, D.
Wang, D.
Wang, D.
Wang, D. Y.
Wang, D.
Wang, D.
Wang, D.
Wang, D.
1305 - Deciphering Transcriptome Alterations in Bone Marrow Hematopoiesis at Single-Cell Resolution in Prolonged Thrombocytopenia after Umbilical Cord Blood Transplantation
3441 - L-Arginine Reinforces NK Cell-Mediated GVL Effect in Bone Marrow of AML Patients with Early Relapse Post-Allo-HSCT
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
3441 - L-Arginine Reinforces NK Cell-Mediated GVL Effect in Bone Marrow of AML Patients with Early Relapse Post-Allo-HSCT
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
Wang, E.
Wang, E. S.
6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
1514 - Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
1515 - Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
2886 - Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in mIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4236 - Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy
4600 - Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
1514 - Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
1515 - Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
2886 - Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in mIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4236 - Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy
4600 - Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data
Wang, F.
1451 - Comprehensive Fusion Gene Landscape in B-Cell Lymphoblastic Leukemia: Insights from Transcriptome Sequencing of 1015 Cases
1467 - Recurrent Focal Mkks-SLX4IP Deletion in ETV6::RUNX1 and Ph/Ph-like B-ALL
3325 - NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma
3595 - High-Accurate Third-Generation Sequencing to Comprehensively Decipher BCR::ABL1 TKIs in-Cis Resistant Mutations
4212 - Advances in B-ALL Diagnosis and Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5 and International Consensus Classification
4323 - Investigation of Viral Gene Transcripts and Viral-Human Gene Fusions in Acute Leukemia Poly(A) RNA-Seq Data
4326 - Extensive Fusion Gene Profiling in Acute Myeloid Leukemia Revealed By Whole Transcriptome Sequencing of 1614 Cases
1467 - Recurrent Focal Mkks-SLX4IP Deletion in ETV6::RUNX1 and Ph/Ph-like B-ALL
3325 - NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma
3595 - High-Accurate Third-Generation Sequencing to Comprehensively Decipher BCR::ABL1 TKIs in-Cis Resistant Mutations
4212 - Advances in B-ALL Diagnosis and Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5 and International Consensus Classification
4323 - Investigation of Viral Gene Transcripts and Viral-Human Gene Fusions in Acute Leukemia Poly(A) RNA-Seq Data
4326 - Extensive Fusion Gene Profiling in Acute Myeloid Leukemia Revealed By Whole Transcriptome Sequencing of 1614 Cases
Wang, F.
Wang, F.
Wang, F.
Wang, F. R.
Wang, F. R.
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
WANG, F.
Wang, F.
Wang, G. G.
Wang, G.
Wang, G. L.
Wang, H.
Wang, H.
Wang, H.
Wang, H.
Wang, H. W.
680 - Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies
863 - A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia
1586 - Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
863 - A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia
1586 - Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
Wang, H. Y.
Wang, H.
Wang, H.
Wang, H. C.
Wang, H.
1022 - Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light‑Chain (AL) Amyloidosis
1443 - Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (R/R Ph+ ALL): First Report from a Phase 1 Study
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
1443 - Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (R/R Ph+ ALL): First Report from a Phase 1 Study
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
Wang, H.
Wang, H.
Wang, H.
Wang, H.
Wang, H.
2109 - Changing Donor Was Critical for the Successful Salvage Second Transplantation for Graft Failure after the First Allogeneic Stem Cell Transplantation: A Chinese Multicenter Retrospective Study
2133 - Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)
2133 - Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)
Wang, H.
Wang, H.
Wang, H.
348 - Deficit of microRNA (miR)-142 Promotes Transformation of Clonal Myeloid Disorder into Acute Myeloid Leukemia (AML)
836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1526 - Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia
1733 - The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
1769 - A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study
1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
1782 - A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients
2215 - Integrating Spatial Transcriptome, Single-Cell Sequencing and Histopathology Reveals Bone Marrow Spatial Heterogenous in AML Patients
2748 - Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia
2944 - Acquired microRNA (miR)-142 Deficit Drives Immune Escape in Acute Myeloid Leukemia (AML)
3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4274 - Impact of Different Therapeutic Regimen on Prognosis in CEBPAbZIP-Inf Acute Myeloid Leukemia
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1526 - Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia
1733 - The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
1769 - A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study
1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
1782 - A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients
2215 - Integrating Spatial Transcriptome, Single-Cell Sequencing and Histopathology Reveals Bone Marrow Spatial Heterogenous in AML Patients
2748 - Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia
2944 - Acquired microRNA (miR)-142 Deficit Drives Immune Escape in Acute Myeloid Leukemia (AML)
3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4274 - Impact of Different Therapeutic Regimen on Prognosis in CEBPAbZIP-Inf Acute Myeloid Leukemia
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
Wang, H.
Wang, H.
438 - SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery
1742 - The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma
1742 - The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma
Wang, H. H.
Wang, H.
1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
Wang, H.
2754 - Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence
4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis
4764 - Single Cell RNA-Seq Analysis Revealed MIF/CD74 Pathway Determinants of BCMA CART Resistance in Relapsed/Refractory Multiple Myeloma
4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis
4764 - Single Cell RNA-Seq Analysis Revealed MIF/CD74 Pathway Determinants of BCMA CART Resistance in Relapsed/Refractory Multiple Myeloma
Wang, J. F.
Wang, J. C.
Wang, J. K.
Wang, J.
1625 - Pretreatment with BTK Inhibitors Could Improve the Sensitivity of DLBCL Cells to CAR-T Cells in Co-Culture System By Down-Regulating the Polarization of M2 Macrophages
4763 - Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
4763 - Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
Wang, J.
Wang, J.
Wang, J.
Wang, J.
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
Wang, J.
328 - Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
2411a - Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2
2734 - CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia
2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
2825 - Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4260 - BL-M11D1, a Novel CD33 Antibody-Drug Conjugate (ADC), in Patients with Relapsed/ Refractory Acute Myeloid Leukemia: Initial Results from First-in-Human Phase 1 Study
4289 - ADGRG1/GPR56 As a Marker of CD8+ Tumor-Reactive T Cells in Acute Myeloid Leukemia
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
2411a - Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2
2734 - CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia
2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
2825 - Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4260 - BL-M11D1, a Novel CD33 Antibody-Drug Conjugate (ADC), in Patients with Relapsed/ Refractory Acute Myeloid Leukemia: Initial Results from First-in-Human Phase 1 Study
4289 - ADGRG1/GPR56 As a Marker of CD8+ Tumor-Reactive T Cells in Acute Myeloid Leukemia
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib
1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia
Wang, J.
Wang, J.
92 - IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
921 - A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
2818 - Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
4647 - A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma
4831 - LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial
- Moderator Introduction
- Data Collection and Monitoring in Decentralized Clinical Trials: Challenges and AI Solutions
527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
921 - A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
2818 - Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
4647 - A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma
4831 - LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial
- Moderator Introduction
- Data Collection and Monitoring in Decentralized Clinical Trials: Challenges and AI Solutions
Wang, J.
Wang, J.
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
3088 - Clinical Outcomes of EBV-Positive Compared to EBV-Negative Diffuse Large B Cell Lymphoma in the Modern Era
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
3088 - Clinical Outcomes of EBV-Positive Compared to EBV-Negative Diffuse Large B Cell Lymphoma in the Modern Era
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
Wang, J.
Wang, J.
486 - First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis
4488 - Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study
4488 - Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study
Wang, J.
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
Wang, J.
836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1457 - Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1plusgenotyping and MRD Assessment in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia
4210 - Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease
1457 - Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1plusgenotyping and MRD Assessment in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia
4210 - Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease
Wang, J.
Wang, J.
1537 - Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
Wang, J.
2099 - Safety and Efficacy of Etoposide Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma
2380 - Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study
3759 - A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI
5025 - The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Hematologic Malignancies
2380 - Optimizing Treatment for Elderly Patients with NDMM Based on Frailty Assessment: A Real-World Observational Study
3759 - A New Frailty Assessment Model Incorporating Gait Speed and Grip Strength for Multiple Myeloma and Consistency Analysis with IMWG-FI
5025 - The Application of Gait Speed and Grip Strength As a Frailty Screening Tool in Elderly Patients with Hematologic Malignancies
Wang, J.
Wang, J.
Wang, J.
Wang, J. Z.
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
Wang, J.
Wang, J.
326 - KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies
943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion
943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion
Wang, J.
Wang, J.
2391 - The Impact of Structural Racism and Social Determinants of Health on Fluorescence in Situ Hybridization Testing Among Patients with Multiple Myeloma
3732 - Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
3732 - Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
Wang, J.
Wang, J.
Wang, J.
Wang, J.
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
Wang, J.
Wang, J.
Wang, J.
Wang, J.
Wang, J. R.
Wang, J.
Wang, J.
Wang, J.
89 - Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies
1447 - Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
2935 - Proteomics and Single-Cell Transcriptomics Reveal Differentiation Patterns of pDC-like LSCs and Poor Prognosis in AML with pDC Expansion
3407 - Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly
3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles
1447 - Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
2935 - Proteomics and Single-Cell Transcriptomics Reveal Differentiation Patterns of pDC-like LSCs and Poor Prognosis in AML with pDC Expansion
3407 - Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly
3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles
Wang, J.
Wang, J.
Wang, J. T.
Wang, J.
Wang, J.
Wang, J.
Wang, K.
Wang, K.
Wang, K.
Wang, K.
Wang, K.
1356 - Super-Enhancer-Associated Long Noncoding RNA Lnc-SPI1U Participates in PU.1 Feedback Regulation By Interacting with HNRNPH1 and Hnrnpf
1547 - Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype
1547 - Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype
Wang, K.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)
4492 - Polatuzumab Vedotin, Zanubrutinib, Rituximab and Lenalidomide (Pola-ZR2) Regimen in the Treatment of Unfit or Frail Patients with Diffuse Large B-Cell Lymphoma
4502.3 - Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
4492 - Polatuzumab Vedotin, Zanubrutinib, Rituximab and Lenalidomide (Pola-ZR2) Regimen in the Treatment of Unfit or Frail Patients with Diffuse Large B-Cell Lymphoma
4502.3 - Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Wang, L.
576 - Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2742 - The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2742 - The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
4399 - Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study
4822 - LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study
4974 - Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology
4822 - LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study
4974 - Practical Microenvironment Classification in Diffuse Large B-Cell Lymphoma Using Digital Pathology
Wang, L.
378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia
Wang, L. L.
Wang, L.
3073 - ΔSUVmax between Baseline and Interim 18f-FDG PET/CT Scans Could Better Assess the Early Response to Induction Therapy and Identify False-Positive Findings at Interim PET/CT in Extranodal NK/T-Cell Lymphoma
4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)
4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)
Wang, L.
4175 - BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
Wang, L. W.
Wang, L.
Wang, L.
Wang, L.
46 - SF3B1 Mutation Drives Loss of Y Chromosome in Chronic Lymphocytic Leukemia
758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
760 - Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter’s Transformation
1061 - Multiomic Discovery of Neopeptides from Non-Canonical ORFs on SF3B1 Mutation-Driven lncRNAs in Leukemia
4484 - Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
760 - Integrating Metabolomics and Molecular Pathways to Uncover Therapeutic Vulnerabilities in Richter’s Transformation
1061 - Multiomic Discovery of Neopeptides from Non-Canonical ORFs on SF3B1 Mutation-Driven lncRNAs in Leukemia
4484 - Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
Wang, L. T.
141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study
4002 - Mutation Analysis of the ADAMTS13 Gene in Patients with Congenital Thrombotic Thrombocytopenic Purpura from the rADAMTS13 Phase 3 Study
4006 - Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study
4002 - Mutation Analysis of the ADAMTS13 Gene in Patients with Congenital Thrombotic Thrombocytopenic Purpura from the rADAMTS13 Phase 3 Study
4006 - Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study
Wang, L.
Wang, L.
50 - A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4+ T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, L. L.
300 - Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
425 - β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
712 - Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
2041 - Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs
2566 - Genetic Associations and Platelet Count Trajectories in Gestational Thrombocytopenia and Immune Thrombocytopenia during Pregnancy
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
425 - β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
712 - Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
2041 - Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs
2566 - Genetic Associations and Platelet Count Trajectories in Gestational Thrombocytopenia and Immune Thrombocytopenia during Pregnancy
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
Wang, L.
Wang, L.
Wang, L.
Wang, L.
Wang, M.
Wang, M.
Wang, M.
1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
Wang, M.
Wang, M.
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
1743 - A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)
2994 - Evaluating Full Antitumor Activities of Monoclonal Antibody and Innate Immune Cells in Relapsed/Refractory Mantle Cell Lymphoma Using Ex Vivo Organoid Platform
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
4454 - Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study
4511.1 - Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma
1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
1743 - A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)
2994 - Evaluating Full Antitumor Activities of Monoclonal Antibody and Innate Immune Cells in Relapsed/Refractory Mantle Cell Lymphoma Using Ex Vivo Organoid Platform
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
4454 - Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study
4511.1 - Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Wang, M.
Wang, M.
Wang, M.
328 - Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia
1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
2734 - CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4289 - ADGRG1/GPR56 As a Marker of CD8+ Tumor-Reactive T Cells in Acute Myeloid Leukemia
1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
2734 - CRISPR-Cas9 Screening Identifies Therapeutic Targets for AML1-ETO Positive Leukemia
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4289 - ADGRG1/GPR56 As a Marker of CD8+ Tumor-Reactive T Cells in Acute Myeloid Leukemia
Wang, M.
Wang, M. C.
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study
5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study
Wang, M.
1896 - Proteasome Shuttle Factor and DNA Repair Protein Rad23A Is a Potential Therapeutic Target in Multiple Myeloma
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
Wang, N.
Wang, N.
Wang, P.
821 - Bone Marrow Microenvironment Dictates the Progression of Clonal Hematopoiesis through Stromal-Macrophage Cell-Cell Interactions
2451 - ICAM4 Mediates Human Erythroid Centered Island Formation
4093 - Germline DDX41 Mutations Disrupt Hematopoiesis and Microenvironment in Patient-Derived Bone Marrow Organoids
2451 - ICAM4 Mediates Human Erythroid Centered Island Formation
4093 - Germline DDX41 Mutations Disrupt Hematopoiesis and Microenvironment in Patient-Derived Bone Marrow Organoids
Wang, P.
Wang, P.
Wang, P.
3028 - Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up
3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up
Wang, P.
Wang, P.
286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
3464 - Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)
3464 - Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)
Wang, P.
Wang, Q.
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
3386 - CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
3386 - CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
Wang, Q.
Wang, Q.
Wang, Q.
Wang, Q. F.
Wang, Q.
477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
1773 - Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML
1803 - The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study
1773 - Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML
1803 - The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study
Wang, Q.
Wang, Q.
Wang, Q.
Wang, Q. Y.
Wang, Q.
Wang, Q.
Wang, R.
2319 - Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
3775 - Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)
3775 - Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)
Wang, R.
Wang, R.
Wang, R.
263 - Targeting the Hypoxic Microenvironment in Cutaneous Chronic Graft-Versus-Host Disease through PI3Kδ Inhibition
3391 - Tissue-Resident Double Negative T Cells Mediate Salivary Gland Damage in Chronic Oral Graft-Versus-Host Disease
4777 - EZH2 Inhibition Alleviates Chronic Graft-Versus-Host Disease By Modulating Lipid Metabolic Reprogramming and Senescence of Neutrophils
3391 - Tissue-Resident Double Negative T Cells Mediate Salivary Gland Damage in Chronic Oral Graft-Versus-Host Disease
4777 - EZH2 Inhibition Alleviates Chronic Graft-Versus-Host Disease By Modulating Lipid Metabolic Reprogramming and Senescence of Neutrophils
Wang, R.
Wang, R.
Wang, S. A.
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
Wang, S.
Wang, S.
Wang, S.
1602 - Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications
4120 - Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications
4120 - Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications
Wang, S.
Wang, S. C.
2804 - The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013
4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia
4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia
Wang, S.
Wang, S.
Wang, S.
Wang, S.
Wang, S.
Wang, S.
Wang, S.
Wang, S.
97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
Wang, S.
Wang, S.
Wang, S.
Wang, S.
Wang, S. Y.
Wang, S. S.
Wang, S.
Wang, S.
Wang, S. M.
Wang, T.
Wang, T.
Wang, T.
Wang, T.
Wang, T.
832 - TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism
1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
1861 - Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)
3385 - BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
4624 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
1875.1 - Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
1861 - Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds
3248 - Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)
3385 - BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
4624 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
1875.1 - Spruce-TN CLL/SLL (cwCLL-002 study): An Ongoing Study of MRD-Guided Sonrotoclax Plus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
Wang, T.
1451 - Comprehensive Fusion Gene Landscape in B-Cell Lymphoblastic Leukemia: Insights from Transcriptome Sequencing of 1015 Cases
4212 - Advances in B-ALL Diagnosis and Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5 and International Consensus Classification
4326 - Extensive Fusion Gene Profiling in Acute Myeloid Leukemia Revealed By Whole Transcriptome Sequencing of 1614 Cases
4212 - Advances in B-ALL Diagnosis and Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5 and International Consensus Classification
4326 - Extensive Fusion Gene Profiling in Acute Myeloid Leukemia Revealed By Whole Transcriptome Sequencing of 1614 Cases
Wang, T. F.
1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
2630 - Management of Upper Extremity Superficial Vein Thrombosis in Patients with Cancer: A Retrospective Observational Cohort Study
4018 - Performance Status, Cancer-Associated Thrombosis, and Bleeding: A Post-Hoc Analysis of the Avert Trial
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
2630 - Management of Upper Extremity Superficial Vein Thrombosis in Patients with Cancer: A Retrospective Observational Cohort Study
4018 - Performance Status, Cancer-Associated Thrombosis, and Bleeding: A Post-Hoc Analysis of the Avert Trial
Wang, V.
Wang, V.
Wang, W.
Wang, W.
1002 - The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population
Wang, W.
WANG, W.
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
Wang, W.
1728 - Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R2) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study
1998 - Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple
1998 - Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple
Wang, W.
Wang, W.
Wang, W.
Wang, W.
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
Wang, W.
Wang, W. H.
Wang, W.
Wang, W.
Wang, W.
Wang, W. H.
Wang, W.
Wang, W.
Wang, W. C.
Wang, X.
Wang, X.
Wang, X.
1671 - Characteristics and Predictors of Early Deaths in Newly Diagnosed Classical Hodgkin Lymphoma
2355 - Analysis of the Nervous System Adverse Events Associated with Blinatumomab: A Real-World Study Using the FDA Adverse Event Reporting System Database
2962 - Phosphorylation-Dependent ANXA2 Relocation on the Membrane and TLR4 Engagement: A Novel Signaling Axis Promoted By PIM1 Mutation in Diffuse Large B Cell Lymphoma
4174 - Selinexor Induces DLBCL Cell Senescence Mediated By USP1/MDMX/p53 Axis
2355 - Analysis of the Nervous System Adverse Events Associated with Blinatumomab: A Real-World Study Using the FDA Adverse Event Reporting System Database
2962 - Phosphorylation-Dependent ANXA2 Relocation on the Membrane and TLR4 Engagement: A Novel Signaling Axis Promoted By PIM1 Mutation in Diffuse Large B Cell Lymphoma
4174 - Selinexor Induces DLBCL Cell Senescence Mediated By USP1/MDMX/p53 Axis
Wang, X.
1547 - Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype
3507 - Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis
3507 - Treatment of Central Nervous System Viral Infections after Allo-HSCT with Intrathecal Donor Lymphocyte Infusion: Feasibility Analysis
Wang, X.
Wang, X.
Wang, X.
Wang, X.
1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
Wang, X. (.
3719 - A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)
3808 - Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
3808 - Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Wang, X.
Wang, X.
263 - Targeting the Hypoxic Microenvironment in Cutaneous Chronic Graft-Versus-Host Disease through PI3Kδ Inhibition
3391 - Tissue-Resident Double Negative T Cells Mediate Salivary Gland Damage in Chronic Oral Graft-Versus-Host Disease
3469 - Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL
4777 - EZH2 Inhibition Alleviates Chronic Graft-Versus-Host Disease By Modulating Lipid Metabolic Reprogramming and Senescence of Neutrophils
3391 - Tissue-Resident Double Negative T Cells Mediate Salivary Gland Damage in Chronic Oral Graft-Versus-Host Disease
3469 - Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL
4777 - EZH2 Inhibition Alleviates Chronic Graft-Versus-Host Disease By Modulating Lipid Metabolic Reprogramming and Senescence of Neutrophils
Wang, X.
Wang, X.
Wang, X.
3066 - Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission
3071 - Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
3071 - Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
Wang, X.
Wang, X.
17 - Leveraging Population-Scale Multiomic Datasets to Elucidate the Risk of Thrombosis Associated with Protein S (PROS1) Deficiency
18 - Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations
133 - Coagulation Factor XII (F12) Haploinsufficiency Is Protective Against Venous Thromboembolism
143 - Using Large-Scale Multiomic Datasets to Assess the Population Frequency of ADAMTS13 Loss-of-Function Variants in the United States and United Kingdom
18 - Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations
133 - Coagulation Factor XII (F12) Haploinsufficiency Is Protective Against Venous Thromboembolism
143 - Using Large-Scale Multiomic Datasets to Assess the Population Frequency of ADAMTS13 Loss-of-Function Variants in the United States and United Kingdom
Wang, X.
Wang, X. S.
Wang, X.
3420 - Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
4816 - Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature
4816 - Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature
Wang, X.
92 - IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
4201 - CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome–Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
4201 - CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome–Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study
Wang, X.
Wang, X.
1723 - Exploration of Rituximab Plus Lenalidomide（R2）in Newly Diagnosed Diffuse Large B Cell Lymphoma with Adverse Prognostic Factors As Maintenance Therapy
4447 - The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma
4447 - The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma
Wang, X.
Wang, X.
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
Wang, X.
Wang, X.
Wang, X.
Wang, X.
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
2513 - Duffy Status and Hydroxyurea Dosing in Adult Patients with Sickle Cell Disease: A Potential for Iatrogenic Harm?
1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
2513 - Duffy Status and Hydroxyurea Dosing in Adult Patients with Sickle Cell Disease: A Potential for Iatrogenic Harm?
1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress
Wang, X.
97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
806 - Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study
1504 - TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial
3047 - TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study
806 - Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study
1504 - TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial
3047 - TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study
Wang, Y. L.
1557 - Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling
1602 - Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications
2214 - Clinical Validation of a Personalized NHL-TME Model System: One-on-One Comparison between Modeled Drug Responses and Patients’ Clinical Responses
1602 - Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications
2214 - Clinical Validation of a Personalized NHL-TME Model System: One-on-One Comparison between Modeled Drug Responses and Patients’ Clinical Responses
Wang, Y. Z.
2545 - PI3K-AKT Pathway Mediates the Imbalance of Macrophage Polarization in Immune Thrombocytopenia Patients
2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
2815 - Blinatumomab Combined with Venetoclax Increasing the Abundance of CD8 T Cell and NK Cell and Improve the Outcome in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia
2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
2815 - Blinatumomab Combined with Venetoclax Increasing the Abundance of CD8 T Cell and NK Cell and Improve the Outcome in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia
Wang, Y.
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
4576 - Heterozygous ddx41 Mutation Drive Age-Dependent Hematopoietic Stem and Progenitor Cell Dysfunction
4576 - Heterozygous ddx41 Mutation Drive Age-Dependent Hematopoietic Stem and Progenitor Cell Dysfunction
Wang, Y.
Wang, Y.
Wang, Y.
2417 - Understanding Improved Survival Among Black Individuals with Myelodysplastic Syndromes
4560 - Risk of Osteoporosis and Osteoporotic Fractures in Patients with Myeloproliferative Neoplasms
5073 - Assessing the Contribution of Duffy Null Phenotype to Disparities in Eligibility Criteria for Clinical Trials for Newly-Diagnosed Colorectal Cancer
5171 - Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group
4560 - Risk of Osteoporosis and Osteoporotic Fractures in Patients with Myeloproliferative Neoplasms
5073 - Assessing the Contribution of Duffy Null Phenotype to Disparities in Eligibility Criteria for Clinical Trials for Newly-Diagnosed Colorectal Cancer
5171 - Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group
Wang, Y.
4347 - Harnessing Ctdna to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study
4481 - Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial
4481 - Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial
Wang, Y.
304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
3937 - Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
3937 - Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)
Wang, Y.
1769 - A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study
1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
Wang, Y.
477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies
4176 - Tgrx-678 Penetrates Blood-Brain Barrier and Exhibits Preclinical Anti-Tumor Activity in Murine Ph+ CNS Leukemia and ALL Models
1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies
4176 - Tgrx-678 Penetrates Blood-Brain Barrier and Exhibits Preclinical Anti-Tumor Activity in Murine Ph+ CNS Leukemia and ALL Models
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib
Wang, Y.
971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1781 - A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3515 - Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects
3535 - Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia
4893 - Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1781 - A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3515 - Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects
3535 - Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia
4893 - Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial
Wang, Y.
WANG, Y.
87 - Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity
2039 - Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control
3403 - Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression
3430 - Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy
4769 - Ezh2 and Intracellular Ca2+ Signals Interdependently Coordinate Gvhd and CAR T Cell Responses
2039 - Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control
3403 - Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression
3430 - Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy
4769 - Ezh2 and Intracellular Ca2+ Signals Interdependently Coordinate Gvhd and CAR T Cell Responses
Wang, Y.
2516 - Self-Administered Acupressure Improves Pain and Quality of Life in Patients with Sickle Cell Disease
2519 - Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease
3881 - Altered Cerebral Functional Connectivity in Patients with Sickle Cell Disease
2519 - Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease
3881 - Altered Cerebral Functional Connectivity in Patients with Sickle Cell Disease
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
1537 - Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World
1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study
2160 - Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation
3511 - Comparison of Two Conditioning Regimens for Haploidentical Stem Cell Transplantation in Patients with Severe Aplastic Anemia
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
4831 - LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial
1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study
2160 - Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation
3511 - Comparison of Two Conditioning Regimens for Haploidentical Stem Cell Transplantation in Patients with Severe Aplastic Anemia
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
4831 - LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial
Wang, Y.
Wang, Y.
Wang, Y.
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
Wang, Y. H.
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
880 - Granulocyte Derived Resistin Induces Classical Monocyte Repartition and Immune Suppression in CMML
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
4579 - Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions
880 - Granulocyte Derived Resistin Induces Classical Monocyte Repartition and Immune Suppression in CMML
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
4579 - Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions
Wang, Y.
857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation
4122 - Identification of Transcriptional Targets of NSD2 and the Underlying Regulatory Mechanism in t(4;14) Multiple Myeloma Cells Using the Slam-Seq and d-TAG Technologies
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4122 - Identification of Transcriptional Targets of NSD2 and the Underlying Regulatory Mechanism in t(4;14) Multiple Myeloma Cells Using the Slam-Seq and d-TAG Technologies
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
Wang, Y.
111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1624 - Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
3732 - Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1624 - Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
3732 - Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Y.
Wang, Z. J.
Wang, Z.
Wang, Z.
Wang, Z.
WANG, Z.
Wang, Z.
1632 - Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV+ Non-Hodgkin Lymphoma (NHL)
1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV+ Non-Hodgkin Lymphoma (NHL)
Wang, Z.
Wang, Z.
Wang, Z.
Wang, Z.
2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia
Wang, Z. D.
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
Wang, Z.
Wang, Z.
Wang, Z.
Wang, Z.
Wang, Z.
Wang, Z.
Wang, Z.
Wang, Z.
1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
4840 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
4840 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
Wang, Z.
Wang’ondu, R.
Wang-Gillam, A.
Wangweerawong, A.
Wani, K. M.
Wannaphut, C.
1240 - Characteristics of Patients with Inflammatory Bowel Disease and Impact on Outcomes Following Heparin-Induced Thrombocytopenia: A 5-Year Nationwide Analysis
4389 - Incidence and Time to Diagnosis of Secondary Malignancies in Patients with Hairy Cell Leukemia: A Systematic Review and Meta-Analysis
4389 - Incidence and Time to Diagnosis of Secondary Malignancies in Patients with Hairy Cell Leukemia: A Systematic Review and Meta-Analysis
Wantzen, C.
Waraich, M.
Ward, C.
772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
3359 - Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial
3359 - Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial
Ward, G.
Ward, N.
Ward, R.
Warden, A.
Ware, R. E.
3 - Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial
289 - Pharmacokinetic (PK)-Guided Dosing of Hydroxyurea for Tanzanian Children with Sickle Cell Anemia
520 - Building Capacity in Sub-Saharan Africa to Address Sickle Cell Disease: The Consortium on Newborn Screening in Africa (CONSA)
541 - Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa: Initial Results of the ASH Consortium on Newborn Screening in Africa (CONSA) Program
542 - Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts
544 - Growth and Puberty in African Children with Sickle Cell Anemia Treated with Hydroxyurea
545 - Hydroxyurea Treatment Reduces Infection Rates in African Children with Sickle Cell Anemia
546 - Hydroxyurea Decreases Transfusion Utilization in Ugandan Children with Sickle Cell Anemia: Main Results from the Alternative Dosing and Prevention of Transfusions (ADAPT) Trial
2242 - Stroke Training, Research, and Education Toward Capacity with Hydroxyurea (STRETCH)
2495 - Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial
4032 - Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching
289 - Pharmacokinetic (PK)-Guided Dosing of Hydroxyurea for Tanzanian Children with Sickle Cell Anemia
520 - Building Capacity in Sub-Saharan Africa to Address Sickle Cell Disease: The Consortium on Newborn Screening in Africa (CONSA)
541 - Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa: Initial Results of the ASH Consortium on Newborn Screening in Africa (CONSA) Program
542 - Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts
544 - Growth and Puberty in African Children with Sickle Cell Anemia Treated with Hydroxyurea
545 - Hydroxyurea Treatment Reduces Infection Rates in African Children with Sickle Cell Anemia
546 - Hydroxyurea Decreases Transfusion Utilization in Ugandan Children with Sickle Cell Anemia: Main Results from the Alternative Dosing and Prevention of Transfusions (ADAPT) Trial
2242 - Stroke Training, Research, and Education Toward Capacity with Hydroxyurea (STRETCH)
2495 - Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial
4032 - Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching
Ware, S.
Waris, S.
Warley, F.
2370 - The Impact of Social Determinants and Diagnostic Inequities in Hodgkin Lymphoma Outcomes: A Comparative Analysis of South America and the United States
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study
Warmka, M. G.
Warner, D.
Warner, M.
235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank
1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank
Warner, S. L.
Warren, E. H.
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3043 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3043 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
Warrington, K.
Warriyar, V. K.
Warsame, R. M.
83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
Wäsch, R.
106 - Machine Learning Based Prediction of One Year Mortality after Allogeneic Hematopoietic Cell Transplantation (alloHCT) Highlights Importance of Pre-Transplant Immunocompetence
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
1436 - Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
1436 - Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
Washington, K.
Washington, S.
Washington, T.
Wasifuddin, M.
Wasik, M.
1602 - Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications
4120 - Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications
4120 - Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications
Wasilewski, S.
Wasmer, M. H.
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
Wass, M.
Wasserman, W.
Wasserstrom, A.
Waszak, W.
Watanabe, A.
Watanabe, A.
Watanabe, E.
Watanabe, K.
Watanabe, K.
Watanabe, M.
Watanabe, O.
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
Watanabe, T.
Watari, T.
366 - Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
Waterman, D. P.
Waters, N. A.
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
Waters, N.
2267 - Toxicity Outcomes in Phase 1 Lymphoma Trials: Variable Reporting with High Use of Minimising Language in Published Abstracts at International Conferences
4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance
5139 - Toxicity Outcomes in Phase 1 Interventional Studies in Plasma Cell Dyscrasias: Heterogeneous Reporting and High Usage of Minimising Language
4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance
5139 - Toxicity Outcomes in Phase 1 Interventional Studies in Plasma Cell Dyscrasias: Heterogeneous Reporting and High Usage of Minimising Language
Waters, N.
Wathan, T.
Wathan, T. K.
Watkins, B.
2366 - The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes
3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
Watkins, J.
Watkins, M. P.
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
Watson, A.
Watson, A.
Watson, A. M.
Watson, E.
Watson, H.
Watson, M.
Watson Saltis, A.
Watson, T.
Wattanachayakul, P.
Wattebled, K. J.
Watters, S. E.
Wattrus, S. J.
Watts, C.
Watts, J. M.
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1514 - Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
1821 - A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
2886 - Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in mIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
4333 - Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML
4600 - Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1514 - Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
1821 - A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
2886 - Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in mIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
4333 - Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML
4600 - Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data
Watts, K.
Watts, M.
Waultier-Rascalou, A.
Waxman, A.
3266 - Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors
3373 - Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study
3779 - Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
3381.1 - A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)
3373 - Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study
3779 - Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
3381.1 - A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)
Wayne, A. S.
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
Wazir, M. H. K.
Waziri, A. D.
Weaver, K. D.
Webb, D. C.
Webb, J. A.
2297 - Prognostic Understanding for Older, Medically Infirm, and/or Frail Recipients of Allogeneic Hematopoietic Cell Transplantation in an Ongoing Seamless Phase 2/3 Randomized Interventional Trial (ACE-BMT)
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
Webb, J.
Webb, K. L.
Webb, S.
Webber, B. R.
Webber, L.
Webber, S. E.
Weber, A.
Weber, D.
264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
Weber, D. M.
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
Weber, I. S.
Weber, S.
Weber, T.
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4394 - Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4394 - Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance
Weberndoerfer, V.
Weberpals, J.
Wechalekar, A. D.
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
4684 - Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis
890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
4684 - Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis
Wechalekar, G.
Wechsler, J. R.
Wee, F.
Weeks, L. D.
Wehrle, J.
Wei, A.
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
Wei, A. H.
51 - Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
653 - DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy
1514 - Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
2941 - Lipidomic Analysis of Flt3-ITD AML Cells Treated with Intensive Chemotherapy and Independent of Concomitant Sorafenib Display a Profile of Increased Susceptibility to Ferroptosis
4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
4605.1 - Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
653 - DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy
1514 - Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
2941 - Lipidomic Analysis of Flt3-ITD AML Cells Treated with Intensive Chemotherapy and Independent of Concomitant Sorafenib Display a Profile of Increased Susceptibility to Ferroptosis
4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
4605.1 - Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)
Wei, C.
Wei, D.
2434 - Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States
3677 - Financial Impact of Treatment Choice in CML: A Comparison of Later Generation TKIs Versus Imatinib for US Patients and Payers
3812 - Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – a Chart Review Study in the United States
5192 - Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis
3677 - Financial Impact of Treatment Choice in CML: A Comparison of Later Generation TKIs Versus Imatinib for US Patients and Payers
3812 - Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – a Chart Review Study in the United States
5192 - Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis
Wei, D.
Wei, G.
Wei, H.
Wei, H.
214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
Wei, H.
1463 - Mapping T-ALL to T Cell Differentiation Trajectory Identifies an ETP-like Subgroup Arrested at an Early Stage of T Cell Development
2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib
2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation
2927 - The Chromatin Accessibility Landscape and Regulatory Network of CD34 Positive Cells in Acute Myeloid Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4533 - Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib
Wei, J.
1401 - The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
2935 - Proteomics and Single-Cell Transcriptomics Reveal Differentiation Patterns of pDC-like LSCs and Poor Prognosis in AML with pDC Expansion
3132 - Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial
3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles
3567 - Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial
4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)
4781 - 3D Live Imaging and Phenotyping of the Subcellular Cytotoxicity in CAR-T Cell Immunotherapy
4782 - Prediction of Organs Toxicity during CAR T-Cell Therapy By Using Cell-Free DNA Markers
2935 - Proteomics and Single-Cell Transcriptomics Reveal Differentiation Patterns of pDC-like LSCs and Poor Prognosis in AML with pDC Expansion
3132 - Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial
3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles
3567 - Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial
4418 - Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)
4781 - 3D Live Imaging and Phenotyping of the Subcellular Cytotoxicity in CAR-T Cell Immunotherapy
4782 - Prediction of Organs Toxicity during CAR T-Cell Therapy By Using Cell-Free DNA Markers
Wei, J. X.
3307 - Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification
3802 - Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis
3802 - Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis
Wei, J.
Wei, J.
1630 - The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma
3015 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
3057 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
4494 - Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)
3015 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
3057 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
4494 - Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)
Wei, M. C.
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
Wei, M.
Wei, Q.
1360 - RHOAG17V Mutation Exhibits Markedly Different Functions in the Presence of TET2 Loss in T-Cells
1740 - The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
3121 - Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial
1740 - The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
3121 - Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial
Wei, S.
2812 - Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
4199 - Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial
Wei, W.
Wei, W.
Wei, W.
Wei, X.
1686 - Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma
1740 - The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
3121 - Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial
4372 - EBV-Infected NKTCL Upregulated MHC-II Imprinted T Cell Exhaustion By Interacting with LAG3
1740 - The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
3121 - Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial
4372 - EBV-Infected NKTCL Upregulated MHC-II Imprinted T Cell Exhaustion By Interacting with LAG3
Wei, X.
576 - Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2742 - The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2742 - The First-in-Class PTPN2/1 Inhibitor Abbv-CLS-484 Disrupts Mitochondrial Renewal and Blocks Tfrc-Mediated PINK1-Prkn-Dependent Mitophagy to Exert Anti-Tumor Activities in ALK-Positive Anaplastic Large Cell Lymphoma
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
Wei, X.
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
4567 - Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China
4567 - Preliminary Results of Patients with Myelofibrosis (MF) from a Phase I Trial of Jab-8263, a Potent BET Inhibitor
Wei, Y.
1740 - The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
3121 - Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
3121 - Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
Wei, Y.
Wei, Z.
378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
4962 - Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)
1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
4962 - Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)
Wei, Z.
3492 - Improved Outcomes with Bu/Cy+Melphalan and Bu/Cy+Thiotepa Regimens in Haploidentical Hematopoietic Stem Cell Transplantation for Non-Down Syndrome Acute Megakaryoblastic Leukemia
3537 - Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation
3546 - Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for 532 Patients with KMT2A-Rearranged Acute Leukemia
3573 - A Pragmatic Monitoring Model for Non-Relapse Mortality Risk Based on Machine Learning in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation
4934 - A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
3537 - Comparable OS and Gffs of ATLG Vs. Ratg for Gvhd Prophylaxis in Pediatric AA Patients Undergoing Transplantation
3546 - Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation for 532 Patients with KMT2A-Rearranged Acute Leukemia
3573 - A Pragmatic Monitoring Model for Non-Relapse Mortality Risk Based on Machine Learning in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation
4934 - A Long-Term Follow-up Retrospective Study of the Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation for Early T-Precursor Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
Weigel, B. J.
Weigert, O.
2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies
4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment
4382 - Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment
Weimer, I.
3722 - Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
3738 - Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events
3738 - Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events
Weimer, N.
Weiming, L.
477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
480 - Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)
1793 - Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3RT618I : A Multi-Centre Retrospective Study
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
480 - Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)
1793 - Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3RT618I : A Multi-Centre Retrospective Study
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
Weinacht, K. G.
Weinberg, K. I.
Weinberg, O. K.
Weinbergerova, B.
Weiner, A.
Weingart, J.
Weinhaeuser, I.
Weinhäuser, I.
944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1350 - The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation
1539 - MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition
2752 - Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors
2775 - Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML
4518 - Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms
1350 - The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation
1539 - MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition
2752 - Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors
2775 - Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML
4518 - Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms
Weinhold, N.
84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
1890 - Tumor Reactive T Cells Drive Clinical Responses to Multiple Myeloma
1952 - The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
1890 - Tumor Reactive T Cells Drive Clinical Responses to Multiple Myeloma
1952 - The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
Weinhold, N.
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4701 - MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study
4701 - MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study
Weinkove, R.
1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)
2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)
Weinschenk, S.
Weinshenker, N.
Weinstein, O.
Weinstock, M.
459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
Weinzerl, E. P.
Weir, B. A.
Weir, J.
Weis, K.
371 - Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias
637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow
2010 - Regulatory T Cell Derived Trefoil Factor 1 Drives Thymic Regeneration in Allogeneic Hematopoietic Cell Transplantation
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow
2010 - Regulatory T Cell Derived Trefoil Factor 1 Drives Thymic Regeneration in Allogeneic Hematopoietic Cell Transplantation
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
Weisdorf, D.
14 - Clonal Hematopoiesis and Venous Thromboembolism Risk in Lymphoma Patients Surviving Autologous Transplantation
403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
2098 - The Impact of Stem Cell Mobilization Regimen on Outcomes after Autologous Transplant for Multiple Myeloma
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report
403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
2098 - The Impact of Stem Cell Mobilization Regimen on Outcomes after Autologous Transplant for Multiple Myeloma
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report
Weisel, J. W.
Weisel, K. C.
84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
497 - Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
497 - Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
Weisemann, S.
Weisenburger, D. D.
Weisenburger, D. D.
Weisinger, J.
Weiss, B. M.
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2780 - Preclinical Proof-of-Concept of a Novel mRNA-Based Therapeutic Combination of an FcRH5 Targeted NK Cell Engager and an IL-15 Superagonist for the Treatment of Multiple Myeloma
4163 - Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma
4430 - Risk of Hematologic Malignancy Following Infectious Mononucleosis Caused By Epstein-Barr Virus: A Danish and Swedish Observational Study over 40 Years
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2780 - Preclinical Proof-of-Concept of a Novel mRNA-Based Therapeutic Combination of an FcRH5 Targeted NK Cell Engager and an IL-15 Superagonist for the Treatment of Multiple Myeloma
4163 - Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma
4430 - Risk of Hematologic Malignancy Following Infectious Mononucleosis Caused By Epstein-Barr Virus: A Danish and Swedish Observational Study over 40 Years
Weiss, G.
Weiss, J.
Weiss, J. M.
Weiss, J. J.
447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
Weiss, L. J.
Weiss, M. J.
146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease
195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
2478 - miRNA-144/451 Regulates Cell Surface TfR1 Expression in Normal and β-Thalassemic Erythroblasts
4031 - Identification of Breakpoints of RHD Hybrid Alleles By Long-Read Sequencing
4088 - Adenine Base Editing Improves Erythropoiesis in Diamond-Blackfan Anemia Syndrome Patient-Derived Induced Pluripotent Stem Cells
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease
195 - Hematopoietic Stem Cells Supporting Fetal Erythropoiesis Are Differentially Regulated By Small and Large Ribosomal Subunits
2478 - miRNA-144/451 Regulates Cell Surface TfR1 Expression in Normal and β-Thalassemic Erythroblasts
4031 - Identification of Breakpoints of RHD Hybrid Alleles By Long-Read Sequencing
4088 - Adenine Base Editing Improves Erythropoiesis in Diamond-Blackfan Anemia Syndrome Patient-Derived Induced Pluripotent Stem Cells
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease
Weiss Santos, L. W.
Weissenboeck, M.
Weissler, K. A.
Weitz, I. C.
Weitz, J.
Weitzman, S.
Weivoda, M.
Welch, J. J.
307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
Welding, I.
Welkie, R. L.
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
4460 - Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
5135 - Comparison of Treatment Outcomes with V-EPOCH Vs DA-EPOCH for First-Line Plasmablastic Disease
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
4460 - Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
5135 - Comparison of Treatment Outcomes with V-EPOCH Vs DA-EPOCH for First-Line Plasmablastic Disease
Wellard, C.
1951 - Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
2385 - Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis
5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
5147 - Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
2385 - Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis
5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
5147 - Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)
Wellbrock, J.
1374 - The PTPN2/PTPN1 Inhibitor Abbv-CLS-484 Augments Immune Responses Against Leukemic Blasts and Impedes Leukemia Cell Proliferation in AML Alone and in Combination with Venetoclax
1397 - CD39 Is Predominantly Expressed in Adverse AML Patients and Blockade By a New Anti-CD39 Nanobody Increases Lysis of AML Blasts
1397 - CD39 Is Predominantly Expressed in Adverse AML Patients and Blockade By a New Anti-CD39 Nanobody Increases Lysis of AML Blasts
Wellendorf, A.
Weller, E.
Weller, J. F.
Wellhausen, N.
Welliver, M.
Welliver, T.
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
Wells, M.
Wells, P. S.
4018 - Performance Status, Cancer-Associated Thrombosis, and Bleeding: A Post-Hoc Analysis of the Avert Trial
4019 - The Incidence and Risk of Venous Thromboembolism in Patients with Active Malignancy and Isolated Superficial Venous Thrombosis: A Systematic Review and Meta-Analysis. (The IROVAM-iSVT review)
4019 - The Incidence and Risk of Venous Thromboembolism in Patients with Active Malignancy and Isolated Superficial Venous Thrombosis: A Systematic Review and Meta-Analysis. (The IROVAM-iSVT review)
Wells, W.
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
Welner, R.
1756 - Immune Content of Mature and Licensed Cytotoxic Cells Is Associated with Treatment-Free Remission in Chronic Myeloid Leukemia
1814 - Distinct Transcriptomic Cell States Differentiate Low-Risk MDS from Healthy Marrow
2648 - Mitochondrial Metabolism Underlies Developmental Programming of Hematopoietic Stem Cell Function By Prenatal Folate
2939 - Combined Human and In Vivo Analyses Implicate the Critical Importance of Acute Myeloid Leukemia Associated CD8 T Cells and Identifies Their Molecular Dysfunction
1814 - Distinct Transcriptomic Cell States Differentiate Low-Risk MDS from Healthy Marrow
2648 - Mitochondrial Metabolism Underlies Developmental Programming of Hematopoietic Stem Cell Function By Prenatal Folate
2939 - Combined Human and In Vivo Analyses Implicate the Critical Importance of Acute Myeloid Leukemia Associated CD8 T Cells and Identifies Their Molecular Dysfunction
Welsh, E. L.
Welsh, J.
Welstead, G. G.
2063 - Optimizing Chimeric Antigen Receptor Endodomains for Effector Function and Cell Expansion in iPSC-Derived T-Cell Therapies
4819 - Successful Generation of iPSC-Derived CD4+ and CD8+ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production
4821 - Universal Cloaking of Allogeneic T Cell Therapies Against Natural Killer Cells Via CD300a Agonism
4819 - Successful Generation of iPSC-Derived CD4+ and CD8+ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production
4821 - Universal Cloaking of Allogeneic T Cell Therapies Against Natural Killer Cells Via CD300a Agonism
Welte, K.
417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia
419 - Flavopiridol Restores Granulopoiesis in an Experimental Model of Severe Congenital Neutropenia
2530 - Genotype-Phenotype Correlations in Patients with Severe Chronic Neutropenia Harboring ELANE Mutations: A Long-Term Study of the Severe Chronic Neutropenia International Registry
4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines
419 - Flavopiridol Restores Granulopoiesis in an Experimental Model of Severe Congenital Neutropenia
2530 - Genotype-Phenotype Correlations in Patients with Severe Chronic Neutropenia Harboring ELANE Mutations: A Long-Term Study of the Severe Chronic Neutropenia International Registry
4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines
Weltge, P.
Welty, N. E.
Wemeau, M.
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
3167 - Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination – a FIM Study
Wen, A.
Wen, B.
Wen, F.
Wen, K.
Wen, Q.
1449 - Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
2902 - Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
2902 - Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
Wen, R.
Wen, S.
822 - Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia
945 - Causes and Consequences of Clonal Hematopoiesis with Unknown Drivers in 409,553 Whole-Genome Sequenced UK Biobank Participants
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
945 - Causes and Consequences of Clonal Hematopoiesis with Unknown Drivers in 409,553 Whole-Genome Sequenced UK Biobank Participants
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
Wen, X. Y.
Wen, X.
Wen, Y.
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
Wen, Z.
Wenbo, Z.
Wendelin, K.
961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013
1436 - Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
1436 - Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
Wendt, K.
1057 - Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy
2917 - Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data
4975 - Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning
2917 - Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data
4975 - Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning
Wendtner, C. M.
Weng, A. P.
Weng, G.
1516 - Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine
4283 - The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study
4283 - The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study
Weng, H.
Weng, J.
477 - Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
Weng, J.
Weng, K.
Weng, L. C.
Weng, N. P.
Weng, R.
Weng, S. J.
Weng, W. K.
69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
4838 - BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti‑CD7 CAR-T-Cells
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
4838 - BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti‑CD7 CAR-T-Cells
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
Weng, X.
Wenge, D. V.
Wenger, A.
Wenger, P.
Wenger, V.
Wenick, S.
Wenjie, X.
832 - TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism
1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
1861 - Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
1861 - Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
Wennström, L.
Wensveen, F.
Wentworth, D.
Wentzel, A.
Wenzel, P. L.
Wenzel, P.
Wenzl, K.
Werling, M.
Wernecke, E.
Werner, A.
Werner, J.
Werth, M.
Wertheim, G.
Wesevich, A. J.
Wesevich, A.
Weßels, W.
Wesson, W.
389 - Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients
2350 - Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)
4708 - An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
5030 - The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART
2350 - Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)
4708 - An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
5030 - The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART
West, B.
189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging
West, C.
West, F. M.
West, J.
West, J.
Westbrook, A.
2366 - The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes
3509 - Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
3509 - Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
Westendorf, A. M.
Wester, R.
676 - Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
Westerberg, E.
Westerman, D.
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
Westerman, M.
3330 - Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma
3371 - Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)
4739 - Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma – Long-Term Follow-up of the HOVON 143 Trial
3371 - Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)
4739 - Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma – Long-Term Follow-up of the HOVON 143 Trial
Westermann, A.
Westermann, F.
Westervelt, P.
224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
2066 - Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
2066 - Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma
Westerweel, P. E.
2554 - The ‘Stop TPO-Receptor Agonist in ITP Patients’ (STIP) Study: Clinical and Immune Modulatory Effects of Romiplostim Tapering
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
Westin, J. R.
579 - Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy
4454 - Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma
5121 - Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study
1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
4511.1 - Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy
4454 - Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma
5121 - Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study
1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
4511.1 - Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Westmark, P. R.
Westmoreland, K. D.
1438 - Understanding the Associations between High-Dose Methotrexate Pharmacokinetics and the Risk of Adverse Events in Children and Adolescents with Down Syndrome Associated High-Risk Acute Lymphoblastic Leukemia
4032 - Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
4032 - Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
Westover, T.
Westrick, R. J.
Wethmar, K.
1436 - Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022
Weyand, A. C.
717 - Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study
2594 - Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD
3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database
3978 - Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset
5021 - Evaluation of Heavy Menstrual Bleeding in Adolescents within the Primary Care Setting
5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time
- Leveraging and Enriching Social Media
- Pediatric Clinical Hematology
2594 - Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD
3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database
3978 - Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset
5021 - Evaluation of Heavy Menstrual Bleeding in Adolescents within the Primary Care Setting
5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time
- Leveraging and Enriching Social Media
- Pediatric Clinical Hematology
Weybright, M. J.
Whangbo, J.
Whayman, M.
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
Wheadon, H.
Wheat, J. C.
Wheeden, K.
Wheeler, A. P.
556 - Combatt HMB-Recon: Combination Therapy in Adolescents to Treat Heavy Menstrual Bleeding-Review of Charts to Observe Treatment Patterns
2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study
3712 - Title: Real-World Utilization of Human Fibrinogen Concentrate in Managing Bleeding in Adult and Pediatric Patients: A Retrospective Study
3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
- Quantifying Menorrhagia and Overview of Non-Surgical Management of Heavy Menstrual Bleeding
2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study
3712 - Title: Real-World Utilization of Human Fibrinogen Concentrate in Managing Bleeding in Adult and Pediatric Patients: A Retrospective Study
3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
- Quantifying Menorrhagia and Overview of Non-Surgical Management of Heavy Menstrual Bleeding
Wheeler, G.
Wheeler, J.
Wheeler, L.
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study
2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study
Whelan, C.
Whelan, S.
Whipp, E. C.
2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
2978 - Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation
3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia
2978 - Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation
3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia
Whisenant, T.
1363 - Defining the Roles of Base Deaminase and Splicing Deregulation in Pediatric B-Cell Acute Lymphoblastic Leukemia Stem Cell Persistence
1385 - Identifying the Impact of ADAR1 Inhibition on LSC Niche Remodeling in 3D Nanobioreactors
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
1385 - Identifying the Impact of ADAR1 Inhibition on LSC Niche Remodeling in 3D Nanobioreactors
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
Whitaker, B.
Whitaker, J. S.
White, D.
1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
1876 - Identification of Novel Protein Biomarkers in Bone Marrow Interstitial Fluid Links Coagulation Cascade Proteins to Survival Outcomes in Multiple Myeloma
1876 - Identification of Novel Protein Biomarkers in Bone Marrow Interstitial Fluid Links Coagulation Cascade Proteins to Survival Outcomes in Multiple Myeloma
White, D.
1996 - Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
3338 - Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
3338 - Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
White, G. C.
White, J. M.
White, J. U.
2250 - Bridging the Gap for Sickle Cell Disease Patient Data in Sub-Saharan Africa By Expanding Access to Specialty Biomarkers and Clinical Trials
2305 - Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)
2305 - Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)
White, K. H.
White, L. S.
White, R.
Whitehead, P.
Whiteheart, S. W.
Whitfield, H. J.
Whiting, J.
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
Whitlock, J. A.
Whitney, D.
Whittaker, T. E.
Whittenburg, J.
Whittington, S.
Whittle, B.
Whitty, J.
Wichapong, K.
Wichelhaus, T. A.
Wick, B.
Wickenhauser, C.
Wickrema, A.
Widhopf II, G. F.
744 - Expression of ROR1 and ROR2 in Hairy Cell Leukemia Cells Enhances Constitutive Activation of ERK1/2 and Cancer Stemness
1852 - ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)
1852 - ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)
Wiebe, D.
Wieczorek, S.
Wieczorkiewicz-Kabut, A.
Wiederschain, D.
Wiedl, C. M.
Wiedmeier-Nutor, J. E.
249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
3269 - A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
3269 - A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
Wieduwilt, M. J.
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
2858 - The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Wiegand, L.
Wielgos-Bonvallet, M.
1701 - Continuous or Fixed-Duration Treatment for CD3xCD20 Bispecifics: A Modeling and Simulation Study Using Epcoritamab Monotherapy
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
Wiemels, J. L.
Wienand, K.
Wienecke, T.
Wienke, A.
Wierda, W. G.
584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1014 - Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
1866 - Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies
1868 - A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
2095 - Gelofusine As Alternative to Dextran40 for Washing Cryopreserved Hematopoietic Stem Cell Products Prior to Infusion: Validation and Application to Clinical Practice
2786 - Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL
3236 - Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
4631 - Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
3257.2 - BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1014 - Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
1866 - Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies
1868 - A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
2095 - Gelofusine As Alternative to Dextran40 for Washing Cryopreserved Hematopoietic Stem Cell Products Prior to Infusion: Validation and Application to Clinical Practice
2786 - Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL
3236 - Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
4631 - Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
3257.2 - BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia
Wiernikowski, J.
Wierzbicka-Hainaut, E.
Wierzbowska, A.
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
Wiestner, A.
3231 - T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
4620 - Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
4620 - Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
Wiethe, S.
Wiethoff, A.
Wigerblad, G.
Wiggers, C. R.
Wiggins, C.
Wight, J.
3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse
4410 - Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress
4410 - Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress
Wiita, A. P.
1038 - HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies
2036 - Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma
2037 - Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia
4646 - CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
4978 - Novel Single-Cell RNA Technology Simplifies Measurement of Anti-BCMA CAR-Ts in Patient Samples
2036 - Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma
2037 - Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia
4646 - CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
4978 - Novel Single-Cell RNA Technology Simplifies Measurement of Anti-BCMA CAR-Ts in Patient Samples
Wijdeveld, L.
Wilbur, D. S.
2014 - CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy
Wilcox, L. J.
2591 - Patient and Caregiver Preferences for Hemophilia Prophylactic Treatments: A Discrete Choice Experiment
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
3581 - In Vitro and In Vivo Potency Differences between AAVRh74var and AAV5 Vectors Encoding the Same High-Activity Human Factor IX Variant, FIX-R338L, Expression Cassette: Implications for Hemophilia B Gene Therapy
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
3581 - In Vitro and In Vivo Potency Differences between AAVRh74var and AAV5 Vectors Encoding the Same High-Activity Human Factor IX Variant, FIX-R338L, Expression Cassette: Implications for Hemophilia B Gene Therapy
Wilcox, R. A.
233 - CDK9 Is a Vulnerability in GATA-3 Driven and MCL-1 Independent T-Cell Lymphomas
858 - Single Cell Atlas of Cutaneous T Cell Lymphomas Reveals XPO1 Dependency
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
3105 - Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma
4477 - Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study
858 - Single Cell Atlas of Cutaneous T Cell Lymphomas Reveals XPO1 Dependency
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
3105 - Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma
4477 - Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study
Wilcox, R. A.
Wilcox, S. R.
Wilde, L.
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
Wildes, T.
Wildes, T. M.
6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
703 - Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
3550 - Pre-Hematopoietic Cell Transplantation (HCT) Frailty Is Associated with Lower Cognitive Function and Health-Related Quality of Life (HRQOL) in Older Adults Undergoing HCT
- Moderator Introduction and Session 1 Initial Audience Voting
703 - Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
3550 - Pre-Hematopoietic Cell Transplantation (HCT) Frailty Is Associated with Lower Cognitive Function and Health-Related Quality of Life (HRQOL) in Older Adults Undergoing HCT
- Moderator Introduction and Session 1 Initial Audience Voting
Wildgust, M.
Wildschut, M.
Wiley, S.
721 - Orally Bioavailable CDK9 Inhibitor Voruciclib Downregulates Oncogenic Pathways in Leukemic Cells from Patients Treated on a Clinical Trial
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4147 - Pharmacodynamic Analysis of Mcl-1 and RNA Pol IISer2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4147 - Pharmacodynamic Analysis of Mcl-1 and RNA Pol IISer2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib
Wiley, S.
Wilhelm, E.
Wilhelm, M.
Wilk, C. M.
Wilke, A.
Wilke, A. C.
Wilkens, L.
Wilkens, S.
Wilkerson, R. G.
Wilkes, D.
Wilkes, J. J.
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
Wilkin, A. M.
Wilkinson, K.
Wilkinson, S.
Will, O.
Willan, J.
Willard, N.
Wille, K.
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
Willems, L.
Willemze, A.
Willen, S.
Willenbacher, E.
Willenbacher, W.
William, B. M.
William, B. M.
Williams, A.
503 - Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy
Williams, A. D.
Williams, A. M.
567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3714 - Neurocognitive Decline Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma
- Promising Biomarkers of Premature Cognitive Aging in Survivors of Adolescent and Young Adult Hodgkin Lymphoma
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3714 - Neurocognitive Decline Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma
- Promising Biomarkers of Premature Cognitive Aging in Survivors of Adolescent and Young Adult Hodgkin Lymphoma
Williams, B.
Williams, C. D.
Williams, C. J.
Williams, D. A.
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
3574 - Gene Therapy for Sickle Cell Disease Is Associated with a Decreased Transplant Length of Stay and Similar Rates of Short-Term Complications Compared to Allogeneic Matched Sibling Stem Cell Transplant: A Single Center Experience
3574 - Gene Therapy for Sickle Cell Disease Is Associated with a Decreased Transplant Length of Stay and Similar Rates of Short-Term Complications Compared to Allogeneic Matched Sibling Stem Cell Transplant: A Single Center Experience
Williams, D. C.
Williams, G.
2387 - Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)
2396 - Functional Decline Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoetic Stem Cell Transplantation
3767 - Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
5145 - Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
2396 - Functional Decline Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoetic Stem Cell Transplantation
3767 - Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
5145 - Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Williams, H.
Williams, J.
Williams, J.
Williams, J.
291 - Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain
5005 - Assessing Social Media Preferences and Developing Digital Health Care Transition Education Materials for Emerging Adults with Sickle Cell Disease: A Mixed Method Pilot Study
5005 - Assessing Social Media Preferences and Developing Digital Health Care Transition Education Materials for Emerging Adults with Sickle Cell Disease: A Mixed Method Pilot Study
Williams, K. M.
2366 - The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes
3509 - Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation
4768 - Human Lung Organoid Model of Bronchiolitis Obliterans Syndrome Following Hematopoietic Cell Transplantation
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
3509 - Terminal Complement Activation in Children with Sinusoidal Obstructive Syndrome after Hematopoietic Cell Transplantation
4768 - Human Lung Organoid Model of Bronchiolitis Obliterans Syndrome Following Hematopoietic Cell Transplantation
4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
Williams, L. S.
Williams, L. D.
Williams, L.
1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy
1918 - Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients
1969 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040
4708 - An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
1918 - Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients
1969 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040
4708 - An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Williams, L. S.
Williams, M.
Williams, M. T.
Williams, M. E.
Williams, N. D.
2675 - Dysregulation of the Ubiquitination Pathway: Insights on Autoinflammatory Conditions and Inborn Errors of Immunity in Bone Marrow Failure Disorders
2918 - Developing a Therapeutic Strategy for Targeting Metabolic Vulnerability of TET2 Mutant Leukemia
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4159 - Loss of TET2 Increases MHC Class I Expression in Acute Myeloid Leukemia
2918 - Developing a Therapeutic Strategy for Targeting Metabolic Vulnerability of TET2 Mutant Leukemia
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4159 - Loss of TET2 Increases MHC Class I Expression in Acute Myeloid Leukemia
Williams, N.
Williams, O.
Williams, P.
Williams, R.
Williams, R.
Williams, S.
Williams, S. P.
Williams, S.
Williams, S.
Williams, T. N.
Williams, T. N.
Williams, Z.
Williamson, A.
Williamson Lewis, R.
Williamson, S.
Willis, C.
146 - SAGES1: Clinical Translation of CRISPR Genome Editing Strategy to Induce Fetal Hemoglobin to Treat Sickle Cell Disease
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
Willis, L.
Willman, C. L.
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4309 - Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4309 - Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG
Willrich, M. A. V.
Willumsen, N.
Wilmington, A.
Wilmoth, J.
Wilson, A.
131 - Real-World Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate and Severe Hemophilia a: An Analysis of the Adelphi Hemophilia Wave III Disease Specific Programme
2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
Wilson, A. J.
Wilson, B. S.
Wilson, C.
Wilson, D. B.
Wilson, D.
Wilson, H. P.
Wilson, I.
Wilson, J.
Wilson, J.
Wilson, K.
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
Wilson, K.
2284 - The Impact of Physiotherapy Prehabilitation on Physical Fitness, Length of Stay (LoS), Readmission Rates, Quality of Life (QoL) and Patient Level Costing (PLICS) for Haematopoietic Stem Cell Transplant (HSCT) and Chimeric Antigen Receptor T- Cell (CAR-T) Recipients
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
Wilson, M. R.
Wilson, N. K.
190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition
2659 - Multimodal Single Cell Analysis Reveals Hematopoietic Changes across the Human Lifespan
4115 - A Novel in Vitro Model of Pre-Leukemic Competition Reveals “Super-Competitive” TET2-Mutant Hematopoietic Stem Cell Clones
2659 - Multimodal Single Cell Analysis Reveals Hematopoietic Changes across the Human Lifespan
4115 - A Novel in Vitro Model of Pre-Leukemic Competition Reveals “Super-Competitive” TET2-Mutant Hematopoietic Stem Cell Clones
Wilson, S.
644 - CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
Wilson, W.
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
4744 - Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial
4744 - Increased Rates of MRD Conversion from Positive (+ve) to Negative (-ve) Following ASCT Compared to Chemotherapy Consolidation in Newly Diagnosed Multiple Myeloma Is Prognostic for Improved Progression Free Survival: Dynamic MRD Assessment in the UK-MRA Cardamon Trial
Wilson, W. H.
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
Wilson, W. H.
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
984 - Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
1724 - A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS
Wilson-Miller, J.
Wiltzius, S.
Wind-Rotolo, M.
1107 - Dual Activation of PKR and PKM2 Reduced the Development of Fibrosis and Iron Deposition in a Sickle Cell Disease Nephropathy Mouse Model
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
Windyga, J.
718 - Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study
2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study
2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study
Winer, E. S.
447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
737 - Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
737 - Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
1489 - Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities
4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Winer, R.
Winestone, L. E.
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
- Management of Refractory and Relapse of ALL in Adolescents and Young Adults
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
- Management of Refractory and Relapse of ALL in Adolescents and Young Adults
Winfree, K. B.
Wingard, J. R.
Winge, S.
Winick, J. H.
Winick, N. J.
1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
Winkler, I. G.
Winkowska, L.
Winograd, B.
1878 - Ktx-1029, a Potent, Selective MMSET/NSD2 Inhibitor Is Effective in t(4;14) Multiple Myeloma Preclinical Models
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
Winroth, A.
Winter, A. M.
459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
3247 - Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®
3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
4499 - Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
3247 - Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®
3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
4499 - Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
Winter, E.
Winter, J. N.
459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
Winter, J. N.
Winter, S. S.
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
1407 - A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
1407 - A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
Winter, S.
1057 - Synthetic Bone Marrow Smears Are a Privacy-Preserving Substitute for Developing Accurate Leukemia Classification Models in Hematological Microscopy
1822 - Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2917 - Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data
1822 - Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2917 - Deep Learning Predicts Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia Solely Based on Bone Marrow Smear Image Data
Winterberg, D.
636 - CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL
914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
Winterborn, A.
Winters, A.
Winters, III, J. P.
Winward, A.
Wirsching, A.
Wirthlin, L.
Wirths, S.
Wischmeyer, J.
Wiseman, D. H.
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
880 - Granulocyte Derived Resistin Induces Classical Monocyte Repartition and Immune Suppression in CMML
3496 - Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation
3615 - Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms - All Clones Are Not Equal
4048 - Prevalence and Significance of Clonal Monocytosis of Undetermined Significance (CMUS) Amongst 431,531 United Kingdom Biobank Participants
880 - Granulocyte Derived Resistin Induces Classical Monocyte Repartition and Immune Suppression in CMML
3496 - Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation
3615 - Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms - All Clones Are Not Equal
4048 - Prevalence and Significance of Clonal Monocytosis of Undetermined Significance (CMUS) Amongst 431,531 United Kingdom Biobank Participants
Wiseman, D. H.
Wiseman, G. A.
Wiseman, T.
1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
Wistinghausen, B.
Wistuba, I.
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Witek, M.
Witkowski, M.
Witman, N.
Witmer, C. M.
Witten, E.
Witthuhn, N.
Wittig, M.
Wittmann, C.
Wittmann Dayagi, T.
Wittmeyer, B. J.
Wittmund, L. E.
Wittnebel, S.
Witzig, T. E.
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1624 - Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
2747 - Cyclin D1 Overexpression in Mantle Cell Lymphoma Causes Cellular Dependence on Microhomology-Mediated End-Joining
2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1624 - Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
2747 - Cyclin D1 Overexpression in Mantle Cell Lymphoma Causes Cellular Dependence on Microhomology-Mediated End-Joining
2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)
Witztum, R.
Wiyani, A.
Wlodarski, M.
442 - Hematological Phenotypes in GATA2 Deficiency Syndrome Arise from Secondary Injuries and Maladaptation to Proliferation
1835 - Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?
2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia
4088 - Adenine Base Editing Improves Erythropoiesis in Diamond-Blackfan Anemia Syndrome Patient-Derived Induced Pluripotent Stem Cells
- Opening Remarks
1835 - Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?
2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia
4088 - Adenine Base Editing Improves Erythropoiesis in Diamond-Blackfan Anemia Syndrome Patient-Derived Induced Pluripotent Stem Cells
- Opening Remarks
Woan, K.
2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Wobst, J.
Woei-A-Jin, S.
466 - Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Woelfel, C.
Woelkers, M.
Woessmann, W.
3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial
Wohlschlaeger, A.
Wohlstadter, J. N.
Wojtarowicz, J.
Wojtylak, S.
Wolach, O.
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy
1762 - Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner
1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen
4476 - Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma
1762 - Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner
1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen
4476 - Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma
Wolanskyj-Spinner, A. P.
Wolber, G.
Wolberg, A. S.
Wolden, S.
Woldie, I. L.
2305 - Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)
Wolf, D.
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial
Wolf, E.
Wolf, J. L.
Wolf, R. C.
Wolf, S.
Wolfarth, A.
Wolfe, E. D.
Wolfe, H. R.
2178 - Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
5096 - Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis
5096 - Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis
Wolfe, J.
Wolfe, Z.
Wolff, A.
Wolff, D.
98 - Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the Agave-201 Study
264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation
264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation
Wolff, T.
Wolfgang Blau, I.
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
Wolfgang, K.
Wolfien, M.
1822 - Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
Wolfson, J.
Wolgast, N.
318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
Woll, P.
Wolschke, C.
2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
Won, J. H.
Won, Y. W.
Wong, A.
Wong, B.
Wong, B. A.
Wong, C. K.
Wong, C. C.
Wong, C. M.
Wong Doo, N.
Wong, F. L.
403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
2411d - Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report
947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
2411d - Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report
Wong, G. G.
Wong, J. W. H.
Wong, J. C.
Wong, J.
775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients
3393 - Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach
4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial
3393 - Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach
4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial
Wong, J. M.
Wong, K.
74 - Eradication of the CLECL1+ CLL Subset That Is Prone to Carrying Novel Genomic Mutations and Promoting a Pro-Tumor Microenvironment By a Series of New Monoclonal Antibodies Reactive with Distinct Target Epitopes
1853 - Infiltration of Malignant B Cells Suppresses and Re-Organizes Lymph Node Fibroblasts in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
1853 - Infiltration of Malignant B Cells Suppresses and Re-Organizes Lymph Node Fibroblasts in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Wong, K. K. W.
Wong Kha Kin, H.
Wong, L. S.
Wong, V.
Wong, W. H.
Wong, W. Y.
Wong, Z.
Woo, H.
189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
Woo, J.
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
2209 - Evaluating Protein Interaction Potential of BCL2 Protein for the Direct Assessment of Inhibitor-Target Engagement in Hematological Cancer
4990 - Fine-Tuned Anti-CD19 CAR-T Cells to Improve Anti-Tumor Activity By Smash Platform
2209 - Evaluating Protein Interaction Potential of BCL2 Protein for the Direct Assessment of Inhibitor-Target Engagement in Hematological Cancer
4990 - Fine-Tuned Anti-CD19 CAR-T Cells to Improve Anti-Tumor Activity By Smash Platform
Woo, T.
Wooahn, K.
2178 - Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
2412 - Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
2412 - Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
Wood, A.
Wood, B. L.
1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1316 - Flow Cytometric Quantitation of CD34+ Progenitors in Peripheral Blood: An Underutilized Tool in Diagnostic Evaluation of Pancytopenia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2837 - Enhanced Flow Cytometry and Next Generation Sequencing Assays for Residual B Lymphoblastic Leukemia (B-ALL) Reveal a Subset with Discordant Results Due to Leukemic Changes Post-Therapy
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1316 - Flow Cytometric Quantitation of CD34+ Progenitors in Peripheral Blood: An Underutilized Tool in Diagnostic Evaluation of Pancytopenia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2837 - Enhanced Flow Cytometry and Next Generation Sequencing Assays for Residual B Lymphoblastic Leukemia (B-ALL) Reveal a Subset with Discordant Results Due to Leukemic Changes Post-Therapy
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
Wood, E. M.
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
5147 - Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)
5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
5147 - Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)
Wood, E. M.
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
Wood, J. P.
Wood, J. C.
Wood, K. C.
Wood, S.
957 - BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin’s Lymphoma
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
4142 - BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
Wood, S.
294 - Higher Hemoglobin Level Correlates with Increased Tissue Oxygenation in a Comprehensive Profile of Hemorheology in Sickle Cell Disease
3876 - Dynamic Cerebral Autoregulation and Blood Pressure Oscillations Reveal the Severity of Autoregulatory Dysfunction in Sickle Cell Disease
3879 - Assessing the Impact of Cognitive Load on Resting State Tissue Oxygen Saturation in Adult Patients with Sickle Cell Disease
3876 - Dynamic Cerebral Autoregulation and Blood Pressure Oscillations Reveal the Severity of Autoregulatory Dysfunction in Sickle Cell Disease
3879 - Assessing the Impact of Cognitive Load on Resting State Tissue Oxygen Saturation in Adult Patients with Sickle Cell Disease
Wood, W. A.
387 - Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
3704 - Impact of Hospital-Acquired Venous Thromboembolism on Surviving Medical Admission: Findings from the Medical Inpatient Thrombosis and Hemostasis Study
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
- Building a National Multiple Myeloma Data Hub to Accelerate Research and Enhance Clinical Care
685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
3704 - Impact of Hospital-Acquired Venous Thromboembolism on Surviving Medical Admission: Findings from the Medical Inpatient Thrombosis and Hemostasis Study
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
- Building a National Multiple Myeloma Data Hub to Accelerate Research and Enhance Clinical Care
Woodcock, D.
Woodley, C.
1788 - QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up
3671 - Bridging the Knowledge Gap: Positive Impact of a Patient-Co-Created Bespoke Information Resource for Young People with Myeloproliferative Disorders
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
3671 - Bridging the Knowledge Gap: Positive Impact of a Patient-Co-Created Bespoke Information Resource for Young People with Myeloproliferative Disorders
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
Woods, A. C.
Woods, E.
Woods, G.
Woods, N.
Woodward, L.
Woodward, L.
Woolcock, B.
Wooldridge, J. T.
Wooliver, D. C.
Wooten, A.
Wootton, P.
Worapongpaiboon, R.
Wörmann, B.
Worst, M. A.
2444 - Cold Agglutinin Disease: Virtual Patient Simulation Improves Performance in Diagnosis and Management
2445 - Educational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments
2445 - Educational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments
Worth, H.
Wossidlo, N.
Woyach, J. A.
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
1875 - Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
2446 - The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists’ Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
2786 - Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL
2978 - Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
4622 - LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton’s Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
4623 - Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
3257.2 - BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia
4422.1 - A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies
4634.1 - Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL
- The Evolving Frontline Management of CLL: Are Triplets Better Than Doublets? How Will We Find Out?
1875 - Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
2446 - The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists’ Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
2786 - Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL
2978 - Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
4622 - LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton’s Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
4623 - Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
3257.2 - BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia
4422.1 - A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies
4634.1 - Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL
- The Evolving Frontline Management of CLL: Are Triplets Better Than Doublets? How Will We Find Out?
Woźnica-Karczmarz, I.
Wrammert, J.
Wren, J.
Wrench, D.
Wright, C.
Wright, G. W.
Wright, H. F.
Wright III, C.
Wright, J. P.
Wright, J.
Wright, J. H.
Wright, M. E.
Wright, M.
Wright, M. P.
Wright, R. J.
Wright, T.
Wroclawska, M.
Wu, B.
933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
2398 - Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
2398 - Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
Wu, B.
Wu, B.
Wu, C. J.
76 - Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia
102 - Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes
335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion
379 - Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
761 - Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
910 - A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy
917 - Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
928 - Deconvolving Immunologic Networks of the AML Marrow Microenvironment with Spatial Multi-Omic Profiling
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
2031 - Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
- Immune Microenvironment and GVL Effects
102 - Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes
335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion
379 - Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
758 - Impaired Response to Oxidative DNA Damage Underlies Genomic Instability in B-Cell Leukemia Driven By RPS15 Mutation
761 - Polyfunctional Effector PD-1+ CD8+ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
910 - A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy
917 - Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
928 - Deconvolving Immunologic Networks of the AML Marrow Microenvironment with Spatial Multi-Omic Profiling
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
2031 - Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
- Immune Microenvironment and GVL Effects
Wu, C. C.
Wu, C. L.
Wu, C. O.
177 - A Machine Learning-Based Workflow for Predicting Transplant Outcome in Patients with Sickle Cell Disease
439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2693 - Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets
3711 - Patient Reported Outcomes in Vexas Syndrome
4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2693 - Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets
3711 - Patient Reported Outcomes in Vexas Syndrome
4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
WU, C.
Wu, D.
WU, D.
Wu, D.
Wu, D.
Wu, D.
99 - A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
222 - Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
1167 - Multicellular Derived S100A8/A9 Maintains Megakaryocytes in an Immature State in Immune Thrombocytopenia
1200 - The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir
1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
1676 - Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era
1781 - A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
1997 - Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3113 - Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP±R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3494 - Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL
3515 - Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects
3523 - Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease
3535 - Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial
3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial
3940 - Obinutuzumab Is a Promising Alternative for the Treatment of Relapsed or Refractory Autoimmune Hematological Disorders
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4750 - Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma
4766 - 5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma
4794 - Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells
4840 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
4843 - A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma
4893 - Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population
222 - Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
1167 - Multicellular Derived S100A8/A9 Maintains Megakaryocytes in an Immature State in Immune Thrombocytopenia
1200 - The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir
1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
1676 - Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era
1781 - A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
1997 - Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3113 - Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP±R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3494 - Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL
3515 - Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects
3523 - Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease
3535 - Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial
3838 - Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial
3940 - Obinutuzumab Is a Promising Alternative for the Treatment of Relapsed or Refractory Autoimmune Hematological Disorders
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4750 - Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma
4766 - 5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma
4794 - Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells
4840 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
4843 - A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma
4893 - Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population
Wu, D.
270 - Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3493 - VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4284 - How to Improve the Efficacy of Venetoclax and Azacitidine（VA）for Newly Diagnosed Acute Myeloid Leukemia？a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML
4442 - Study of Autologous Versus Allogeneic Stem Cell Transplantation in 56 Patients with Advanced High-Risk Extranodal NK/T-Cell Lymphoma
4836 - Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3493 - VA Combined with Mbucy Conditioning Regimen Followed By Allo-HSCT Can Improve Survival of High-Risk AML Patients: A Prospective, Single-Center, Single-Arm Clinical Trial
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4284 - How to Improve the Efficacy of Venetoclax and Azacitidine（VA）for Newly Diagnosed Acute Myeloid Leukemia？a Prospective, Single-Center, Single-Arm, Phase 2 Trial for New Diagnosed AML
4442 - Study of Autologous Versus Allogeneic Stem Cell Transplantation in 56 Patients with Advanced High-Risk Extranodal NK/T-Cell Lymphoma
4836 - Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
Wu, D.
1769 - A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study
1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial
4158 - Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia
1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial
4158 - Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia
Wu, D.
Wu, F.
3382 - Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
3388 - Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Wu, F.
2754 - Vincristine Overcomes Cytarabine Resistance in Acute Myeloid Leukemia By Suppression of ARHGAP18-Mediated Cellular Senescence
4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis
4301 - Elevated Circulating CD10¯ G-MDSC-like Neutrophils of Acute Myeloid Leukemia Patients in Complete Remission Status Are Correlated with Relapse and Poor Prognosis
Wu, F.
Wu, F.
Wu, G.
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Wu, G.
Wu, H.
Wu, H.
Wu, H.
Wu, J. F.
Wu, J.
Wu, J.
Wu, J.
576 - Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
1709 - Clinical Implications of Ctdna-Based Minimal Residual Disease Detection in Newly Diagnosed Diffuse Large B-Cell Lymphoma
1725 - Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma：a Phase 2 Multicenter Study
2961 - Multi-Omics Profiling Reveals Tumor Cellular Landscape and Metabolism Remodeling during Extranodal Natural Killer/T-Cell Lymphoma (ENKTL) Metastasis and Progression
1742.3 - A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
Wu, J.
Wu, J.
1188 - Efficacy of Combined Herombopag and Recombinant Human Thrombopoietin Therapy Compared to Monotherapy on Platelet Engraftment after Autologous Hematopoietic Stem Cell Transplantation in Patients
1193 - Herombopag for Preventing Chemotherapy-Induced Thrombocytopenia in Lymphoma: A Single Center, Randomized Controlled, Phase II Study
1193 - Herombopag for Preventing Chemotherapy-Induced Thrombocytopenia in Lymphoma: A Single Center, Randomized Controlled, Phase II Study
Wu, J.
Wu, J.
Wu, J.
Wu, J.
Wu, J.
Wu, K. L.
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
Wu, K.
Wu, K.
Wu, K.
Wu, L.
Wu, L. X.
Wu, L.
Wu, L.
Wu, M.
782 - Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma
3008 - Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study
3648 - Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States
5029 - Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective
3008 - Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study
3648 - Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States
5029 - Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective
Wu, M.
378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
2134 - The Optimal Dose of Anti-Thymocyte Globulin in Beta-Thalassemia Major Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation: A Single-Center, Open-Label, Randomized, Controlled Clinical Study
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
2134 - The Optimal Dose of Anti-Thymocyte Globulin in Beta-Thalassemia Major Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation: A Single-Center, Open-Label, Randomized, Controlled Clinical Study
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China
Wu, M. X.
Wu, M.
Wu, M.
1752 - Anti-Hemojuvelin Monoclonal Antibody Alleviated Anemia Induced By Ruxolitinib Treatment in Mice
2460 - Inhibition of Glycine Transporter 1 Reduces Phototoxicity in a Mouse Model of Erythropoietic Protoporphyria (EPP)
3849 - Anti-Hemojuvelin Monoclonal Antibody Reverses Anemia and Exerts Disease-Modifying Effects in a Mouse Model of Inflammatory Bowel Disease
2460 - Inhibition of Glycine Transporter 1 Reduces Phototoxicity in a Mouse Model of Erythropoietic Protoporphyria (EPP)
3849 - Anti-Hemojuvelin Monoclonal Antibody Reverses Anemia and Exerts Disease-Modifying Effects in a Mouse Model of Inflammatory Bowel Disease
Wu, P.
Wu, Q.
Wu, Q. V.
971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
Wu, Q. V.
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4919 - A Comparison of Different Comorbidity Indices in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Comprehensibility Vs Simplicity Vs Objectivity
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4919 - A Comparison of Different Comorbidity Indices in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Comprehensibility Vs Simplicity Vs Objectivity
Wu, Q.
Wu, Q. C.
Wu, R.
141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study
3971 - The R and CI Values from Thromboelastography (TEG) May be the Risk Predictors for Low-Dose Emicizumab in Chinese Pediatric Hemophilia Patients
3971 - The R and CI Values from Thromboelastography (TEG) May be the Risk Predictors for Low-Dose Emicizumab in Chinese Pediatric Hemophilia Patients
Wu, S. J.
Wu, S. J.
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
1726 - Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1726 - Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Wu, S. J.
1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study
Wu, S.
Wu, S. Y.
Wu, T.
488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
Wu, T.
38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia
599 - Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma
2164 - Long-Term Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Resistant Ph+ Acute B Lymphoblastic Leukemia That Cannot Get MRD- Remission after Multi-Line Treatment
3467 - The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT
3544 - Chimeric Antigen Receptor T Cell Therapy Bridged to the Second Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Toxicity Conditioning for B-Cell Acute Lymphoblastic Leukemia Relapsed after the First Transplant
4225 - NOTCH1 gene Fusions Occur Frequently in Refractory or Relapsed (R/R) T-Cell Lymphomablastic Lymphoma
4922 - Influence of Somatic and Germline Gene Variants on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
599 - Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma
2164 - Long-Term Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Resistant Ph+ Acute B Lymphoblastic Leukemia That Cannot Get MRD- Remission after Multi-Line Treatment
3467 - The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT
3544 - Chimeric Antigen Receptor T Cell Therapy Bridged to the Second Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Toxicity Conditioning for B-Cell Acute Lymphoblastic Leukemia Relapsed after the First Transplant
4225 - NOTCH1 gene Fusions Occur Frequently in Refractory or Relapsed (R/R) T-Cell Lymphomablastic Lymphoma
4922 - Influence of Somatic and Germline Gene Variants on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
Wu, T.
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Wu, T. K.
Wu, W. B.
Wu, W.
Wu, W.
Wu, W.
Wu, X.
Wu, X.
Wu, X.
Wu, X.
Wu, X.
468 - Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma
775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients
4776 - Donor T-Derived Memory Progenitors Differentiated into CD103+/- CXCR6+CD4+ Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease
775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients
4776 - Donor T-Derived Memory Progenitors Differentiated into CD103+/- CXCR6+CD4+ Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease
Wu, X.
Wu, Y.
Wu, Y. J.
Wu, Y.
Wu, Y. F.
Wu, Y.
Wu, Y.
Wu, Y.
312 - Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia
4214 - Single-Cell Sequencing Analysis Reveals Cellular Dynamics Underlying Different Responses to Blinatumomab in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
4214 - Single-Cell Sequencing Analysis Reveals Cellular Dynamics Underlying Different Responses to Blinatumomab in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
Wu, Y.
893 - Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study
1694 - Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring
3062 - Reduction of Radiotherapy Intensity after Achieving Complete Remission with Induction Chemotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma: A Prospective Study
4659 - Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma
1694 - Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring
3062 - Reduction of Radiotherapy Intensity after Achieving Complete Remission with Induction Chemotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma: A Prospective Study
4659 - Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma
Wu, Y.
Wu, Y.
1686 - Efficacy and Safety of a New Regime Containing PD1 Antibody and Pegaspargase for Advanced-Stage or Relapsed/Refractory Natural Killer/T Cell Lymphoma
2109 - Changing Donor Was Critical for the Successful Salvage Second Transplantation for Graft Failure after the First Allogeneic Stem Cell Transplantation: A Chinese Multicenter Retrospective Study
2109 - Changing Donor Was Critical for the Successful Salvage Second Transplantation for Graft Failure after the First Allogeneic Stem Cell Transplantation: A Chinese Multicenter Retrospective Study
Wu, Y.
1305 - Deciphering Transcriptome Alterations in Bone Marrow Hematopoiesis at Single-Cell Resolution in Prolonged Thrombocytopenia after Umbilical Cord Blood Transplantation
3441 - L-Arginine Reinforces NK Cell-Mediated GVL Effect in Bone Marrow of AML Patients with Early Relapse Post-Allo-HSCT
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
3441 - L-Arginine Reinforces NK Cell-Mediated GVL Effect in Bone Marrow of AML Patients with Early Relapse Post-Allo-HSCT
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail
Wu, Y. Z.
Wu, Y. C.
Wu, Y.
Wu, Z.
Wu, Z.
Wu, Z.
34 - T Cell Receptor Clonal Dynamics and Hematopoietic Recovery after Immunotherapy in Severe Aplastic Anemia
1309 - Different Effects of Selective Janus Kinase (JAK) Inhibitors in Murine Bone Marrow Failure
2693 - Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets
4056 - Single-Cell Multi-Omics Analysis Reveals Dysfunctional Features of the Immune Responses in Vexas Syndrome
1309 - Different Effects of Selective Janus Kinase (JAK) Inhibitors in Murine Bone Marrow Failure
2693 - Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets
4056 - Single-Cell Multi-Omics Analysis Reveals Dysfunctional Features of the Immune Responses in Vexas Syndrome
Wu, Z.
Wu, Z.
Wu, Z.
Wubbena, K.
Wucherpfennig, K. W.
Wufsus, A.
Wuhrer, M.
Wuichet, K.
Wujcik, D.
Wulf, G.
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
4495 - Combining Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in Relapsed or Refractory Central Nervous System Lymphoma – a Retrospective Clinical Study
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
4495 - Combining Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in Relapsed or Refractory Central Nervous System Lymphoma – a Retrospective Clinical Study
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
Wulfert, M.
Wulfridge, P.
Wuliji, N.
Wun, T.
Wunderle, L.
738 - Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
3052 - Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study
3052 - Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study
Wunderlich, M.
Wuppalapati, A. S.
Wurm, A. A.
Wurm, A. A.
Wurm-Kuczera, R.
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
Wuthrich, B.
Wyche, P.
Wydra, D.
Wylam, M. E.
Wynn, R.
373 - Significant Incidence of Mixed Donor Chimerism Despite TBI Conditioning in Paediatric B-ALL Patients Bridged to Transplant with Blinatumomab – a Report from the UK and Ireland Paediatric Bone Marrow Transplant/Cellular Therapies Group
925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3455 - Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia: Results of a Prospective Phase I/II Clinical Trial
5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I
925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3455 - Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia: Results of a Prospective Phase I/II Clinical Trial
5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I
Wynne, K.
Wynne-Cattanach, K.
2256 - Relationship between Frequency of Treatment Administration, Adherence to Treatment, and Quality of Life in Patients with Hemophilia a or Hemophilia B, with or without Inhibitors: A Real-World Survey
3973 - Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific ProgrammeTM
5082 - Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients
3973 - Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific ProgrammeTM
5082 - Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients
Wypyszczak, K.
Wysokinska, E. M.
Wysokinski, W.
Wysota, M.
Wyssenbach, M.